Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 8381. Отображено 100.
12-01-2012 дата публикации

Blood coagulation inducing polymer hydrogel

Номер: US20120009242A1
Автор: Adam Behrens, Bartley P. Griffith, Brendan J. Casey, Peter Kofinas, Trevor A. Snyder
Принадлежит: University of Maryland at Baltimore, UNIVERSITY OF MARYLAND AT COLLEGE PARK

The present application is drawn to a synthetic, polymer hydrogel-based material, which is able to actively induce the body's natural hemostatic coagulation process in blood or acellular plasma. The present invention provides the development of a primary amine containing polymer hydrogel capable of inducing blood coagulation and delivering therapeutics for hemostatic or wound care applications, and a method of forming such a primary amine containing polymer hydrogel capable of inducing the blood coagulation process. The primary amine containing polymer hydrogel is able to achieve the same end result as biological-based hemostatics, without the innate risk of disease transmission or immunological response, and at a fraction of the price. Furthermore, due to its inherent hydrogel-based design the material has the capability of arresting blood loss while simultaneously delivering therapeutics in a controlled manner, potentially revolutionizing the way in which wounds are treated.

Подробнее
Номер записи: 1
26-01-2012 дата публикации

Bone cement system for bone augmentation

Номер: US20120022542A1
Автор: Andreas Boger, Christoph Sattig, Stefan Deusser
Принадлежит: Synthes USA LLC

A bone cement is provided that includes a solid component and a liquid component. The solid component and liquid component are mixed together to form the bone cement. After completion of the solid and liquid component mixing, the bone cement has an initial viscosity effective for manual application or manual injection onto or into a targeted anatomical location, e.g., bone, and the cement has stable viscosity range that over both time and temperature is effective for uniformly filling the targeted anatomical location, for example an osteoporotic bone or a fractured vertebral body, with minimal to no leakage of the cement from the targeted anatomical location. Additionally, both the initial viscosity and the stable viscosity of the bone cement are within a range that renders the bone cement effective for injection with a manually operated syringe or multiple syringes.

Подробнее
Номер записи: 2
02-02-2012 дата публикации

Osteoarthritis treatment and device

Номер: US20120029522A1
Автор: Charles F. Leinberry, Peter F. Sharkey
Принадлежит: Knee Creations LLC

A method for treating arthritis of a joint includes identifying a bone lesion in a bone adjacent to the joint; and implanting in the bone a reinforcing member in or adjacent to the bone lesion. A kit for conducting the method includes: (a) at least one reinforcing member having a proximal face adapted to face the joint, a distal face adapted to face away from the joint, and a wedge-shaped edge adapted to pierce bone, wherein the at least one reinforcing member is planar and sterile; and (b) a container adapted to maintain the at least one reinforcing member sterile. Another kit includes: (a) a sterile fluid; (b) a syringe for injecting the fluid into a bone; (c) a curing agent adapted to cure the fluid to polymerize and/or cross-link; and (d) a container adapted to maintain the sterility of contents of the container.

Подробнее
Номер записи: 3
09-02-2012 дата публикации

Bone cement composition, bone cement composition kit and forming method of bone cement hardened material

Номер: US20120035296A1
Автор: Hiroaki Nishii, Koji Goto, Masashi Imamura, Takashi Nakamura, Takehiro Shibuya, Tokuo Suita, Yoshimichi Ueda
Принадлежит: Ishihara Sangyo Kaisha Ltd, KYOTO UNIVERSITY

The invention has as its objects the provision of a bone cement composition, a bone cement composition kit for obtaining the bone cement composition, and a production method of a bone cement hardened material, which are short in doughing time that is a time required to become a state in which a good handling operation can be conducted, and have consequently capable of achieving a high working efficiency by shortening the time required before the handling operation is started. The bone cement composition of the invention contains large-diameter (meth)acrylate polymer particles having an average particle diameter of 10 to 60 μm, small-diameter (meth)acrylate polymer particles having an average particle diameter of 0.1 to 2.0 μm, a (meth)acrylate monomer and a polymerization initiator, wherein the content of the small-diameter (meth)acrylate polymer particles is 5 to 30% by mass based on the total mass of the small-diameter (meth)acrylate polymer particles and the large-diameter (meth)acrylate polymer particles.

Подробнее
Номер записи: 4
09-02-2012 дата публикации

Osteoarthritis treatment and device

Номер: US20120035609A1
Автор: Charles F. Leinberry, Peter F. Sharkey
Принадлежит: Knee Creations LLC

A method for treating arthritis of a joint includes identifying a bone lesion in a bone adjacent to the joint; and implanting in the bone a reinforcing member in or adjacent to the bone lesion. A kit for conducting the method includes: (a) at least one reinforcing member having a proximal face adapted to face the joint, a distal face adapted to face away from the joint, and a wedge-shaped edge adapted to pierce bone, wherein the at least one reinforcing member is planar and sterile; and (b) a container adapted to maintain the at least one reinforcing member sterile. Another kit includes: (a) a sterile fluid; (b) a syringe for injecting the fluid into a bone; (c) a curing agent adapted to cure the fluid to polymerize and/or cross-link; and (d) a container adapted to maintain the sterility of contents of the container.

Подробнее
Номер записи: 5
01-03-2012 дата публикации

Adhesive structure with stiff protrusions on adhesive surface

Номер: US20120052234A1
Автор: Audrey Yoke Yee HO, Chee Tiong Lim, Hong Yee Low, Isabel Rodriguez, Kevin Cooper, Murty N. Vyakarnam, Noha ELMOUELHI, Sriram Natarajan
Принадлежит: Advanced Technologies and Regenerative Medicine LLC, Agency for Science Technology and Research Singapore

An adhesive structure is provided comprising a surface from which extend substantially cylindrical protrusions comprising a stiff resin having a Young's modulus of greater than 17 MPa. The protrusions are of sufficiently low diameter to promote adhesion by physical attractive forces, e.g., Van der Waals attractive forces, as measured by shear adhesion between the adhesive structure and a target surface. A method for preparing the structure is provided as well as a combination of the adhesive structure and target surface.

Подробнее
Номер записи: 6
15-03-2012 дата публикации

Degradable hemostatic sponge and extrusion system and method for manufacturing the same

Номер: US20120065604A1
Автор: Chao-Fu Chang, Kent Kuohua Chang
Принадлежит: Bioeconeer Inc

A degradable hemostatic sponge that can be self-degraded and absorbed by a human body has poly lactic acid as its main material and mixed with a moisture-absorbent material, such as collagen, chitosan, starch and the like, at a specific ratio. Given grinding, mixing and melting steps, the materials using a supercritical fluid as a foaming agent can be used to manufacture the degradable hemostatic sponge having an open-cell microcellular form by a continuous extrusion foaming process. In addition, the present invention also includes a system and a method for manufacturing the degradable hemostatic sponge.

Подробнее
Номер записи: 7
29-03-2012 дата публикации

Applicators for patches and adhesives

Номер: US20120078293A1
Автор: Adi Azran, Eyal Hendel, Havazelet Bianco-Peled, Noam Hassidov, Ohad Kimhi, Rebecca Bank, Rina Lev, Ronit Langzam-Sinai, Shlomo Lewkowicz, Tehilla Bar-Yehuda
Принадлежит: Technion Research and Development Foundation Ltd

Apparatus is provided for use with a tubular structure ( 2 ) in a body of a patient. The apparatus includes an adhesive including first and second components, a container ( 27 ), one or more patches ( 3 ), and an applicator ( 1 ). The container ( 27 ) contains the first component of the adhesive and not the second component of the adhesive. The one or more patches ( 3 ) include the second component of the adhesive and not the first component of the adhesive. The applicator ( 1 ) is configured to removably hold the one or more patches ( 3 ), and to place the one or more patches ( 3 ) at least partially around the tubular structure ( 2 ). Other embodiments are also described.

Подробнее
Номер записи: 8
05-04-2012 дата публикации

Antimicrobial adhesive system

Номер: US20120083536A1
Автор: David D. Cox, Leland W. Annett, Robert E. Lund
Принадлежит: Individual

An adhesive composition having dispersed therein a broad spectrum antimicrobial agent for use in medical applications, such as an adhesive for surgical drapes, wound dressings and tapes, is provided. The adhesive is composed of acrylic polymers, tackifiers and a preferred antimicrobial agent, diiodomethyl-p-tolylsulfone. The subject adhesive composition may be formulated as either an essentially solventless hot melt, or as a solvent based system wherein an emulsion of the antimicrobial agent and the removal of excess solvent is avoided.

Подробнее
Номер записи: 9
26-04-2012 дата публикации

Osteoinductive bone graft injectable cement

Номер: US20120100225A1
Автор: William F. Mckay
Принадлежит: WARSAW ORTHOPEDIC INC

Osteoconductive bone graft materials are provided. These compositions contain injectable cements and demineralized bone matrix fibers. The combination of these materials enables the filling of a bone void while balancing strength and resorption.

Подробнее
Номер записи: 10
10-05-2012 дата публикации

Composite bone cements with a pmma matrix, containing bioactive antibacterial glasses or glassceramics

Номер: US20120115981A1
Автор: Alessandro Bistolfi, Alessandro Masse, Enrica Verne', Giovanni Maina, Marta Miola, Maurizio Crova, Sara Ferraris
Принадлежит: POLITECNICO DI TORINO, Universita degli Studi di Torino

A bone cement comprising an acrylic polymeric component and an inorganic component comprising a bioactive glass or glass-ceramic, comprising at least one metal oxide having an anti-bacterial activity, wherein said glass or glass-ceramic component is adapted to release ions of said metal in contact with physiological fluids. The bone cement performs a sustained antibacterial action, also promoting binding with the tissues with which it is contacted, and it is advantageously employed in the fixation of orthopaedic prostheses, in the production of temporary prostheses and in spinal surgery.

Подробнее
Номер записи: 11
24-05-2012 дата публикации

Preparation of bone cement compositions

Номер: US20120129761A1
Автор: Eva Liden, Jeffrey C. Karr, Malin Nilsson, Veronica Sandell
Принадлежит: Bone Support AB

A method for the preparation of injectable ready-to-use paste bone cement compositions by mixing a dry inorganic bone cement powder comprising a particulate calcium sulfate hemihydrate capable of hardening in vivo by hydration of the calcium sulfate hemihydrate forming calcium sulfate dihydrate, an aqueous liquid and an additive that normally retards the setting process, said method comprising a) providing a bone cement powder comprising calcium sulfate hemihydrate, an accelerator for the hardening of the calcium sulfate hemihydrate by hydration, said accelerator being selected from the group consisting of saline and calcium sulfate dihydrate, and a powdered calcium phosphate component b) mixing the bone cement powder with the aqueous liquid for a period of time c) leaving the mixture for the time needed for allowing the hydration reaction of the calcium sulfate hemihydrate to proceed and allowing calcium sulfate dihydrate crystals to form and grow, and d) admixing the additive by means of a short-duration mixing using a minimum of energy surprisingly shortens the setting times for the cement comprising the additive that retard the setting process to the level observed in the absence of the additive and enables a complete hydration of calcium sulfate hemihydrate to calcium sulfate dihydrate, even when using additives else preventing the hardening.

Подробнее
Номер записи: 12
16-08-2012 дата публикации

Reinforced surgical adhesives and sealants and their in-situ application

Номер: US20120209319A1
Автор: Havazelet Bianco-Peled, Ohad Kimhi
Принадлежит: Technion Research and Development Foundation Ltd

In situ application of reinforced adhesive: applying uncured and curable matter to a surface, applying biocompatible inert reinforcing agent comprising at least one curing agent to the uncured composition; allowing curing within subject, cured composition together with the added reinforcing agent being configured to have improved mechanical support and strength.

Подробнее
Номер записи: 13
27-09-2012 дата публикации

Reversible oral adhesive gel

Номер: US20120244103A1
Автор: George John Orban, John Alexander Staton, Robert J. Davis
Принадлежит: Individual

The invention relates to a reversible oral adhesive gel. The reversible oral adhesive gel is suitable for application to lips to inhibit oral (mouth) breathing and to promote nasal breathing and thereby prevent or ameliorate snoring and to correct other respiratory problems.

Подробнее
Номер записи: 14
25-10-2012 дата публикации

Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices

Номер: US20120270810A1
Автор: Guy Tomer, Orahn Preiss-Bloom
Принадлежит: Lifebond Ltd

Improved matrix or hydrogel that is formed by enzymatic crosslinking of polymers wherein the crosslinking enzyme molecules have been modified for the purpose of improving the crosslinking density, mechanical properties, or other properties of the matrix, and/or to provide improved control over the rate and/or extent of crosslinking, wherein the enzyme molecules are modified to alter the perceived volume of the enzyme molecules in the crosslinked matrix being formed. Methods of production and of use are also provided.

Подробнее
Номер записи: 15
31-01-2013 дата публикации

Kit and method for producing bone cement

Номер: US20130030058A1
Автор: Hubert Büchner, Sebastian Vogt
Принадлежит: HERAEUS MEDICAL GMBH

A kit for producing bone cement includes at least one paste A and one paste B. Paste A contains at least one monomer (a1) for radical polymerization; at least one polymer (a2) insoluble in monomer (a1); at least one polymer (a3) soluble in monomer (a1); and at least one radical polymerization initiator (a4). The weight ratio of the at least one polymer (a2) to the at least one polymer (a3) is at least 2 to 1. Paste B contains at least one monomer (b1) for radical polymerization; at least one polymer (b2) and at least one accelerator (b3) soluble in monomer (b1); and optionally a polymer (b4) insoluble in monomer (b 1 ). The maximum quantity of polymer (b4) is 5% by weight, relative to the total weight of paste B. The weight ratio of polymer (b4) to the at least one polymer (b2) is no more than 0.2.

Подробнее
Номер записи: 16
14-02-2013 дата публикации

Injectable, load-bearing cell/microbead/calcium phosphate bone paste for bone tissue engineering

Номер: US20130039990A1
Автор: Huakun Xu, Michael Weir
Принадлежит: University of Maryland at Baltimore

The invention provides injectable, stem cell-containing calcium phosphate bone pastes for bone tissue engineering and methods of making and using the same.

Подробнее
Номер записи: 17
28-03-2013 дата публикации

METHOD OF PROVIDING HEMOSTASIS USING FLEXIBLE BIORESORBABLE FOAM

Номер: US20130079300A1
Автор: Halversen Matthew J., Hodge Aimee, Oliver Dana A.
Принадлежит: Medtronic Xomed, Inc.

A method of providing hemostasis of bleeding tissue. A flexible bioresorbable foam is formed that consists essentially of carboxymethylcellulose. The flexible bioresorbable foam is crosslinked. Chain scission is performed on the crosslinked flexible bioresorbable foam to provide the flexible bioresorbable foam with a selected in-vivo residence time of between about 3 days and about 14 days. Hemostasis is caused by applying the flexible bioresorbable foam to bleeding tissue. The flexible bioresorbable foam is resorbed in-vivo. The selected in-vivo residence time is a time between the flexible bioresorbable foam being applied to the tissue and the flexible bioresorbable foam having been substantially completely absorbed into the tissue. 1. A method of providing hemostasis of bleeding tissue , wherein the method comprises:forming a flexible bioresorbable foam that consists essentially of carboxymethylcellulose;crosslinking the flexible bioresorbable foam;performing chain scission on the crosslinked flexible bioresorbable foam to provide the flexible bioresorbable foam with a selected in-vivo residence time of between about 3 days and about 14 days;causing hemostasis by applying the flexible bioresorbable foam to bleeding tissue; andresorbing the flexible bioresorbable foam in-vivo, wherein the selected in-vivo residence time is a time between the flexible bioresorbable foam being applied to the tissue and the flexible bioresorbable foam having been substantially completely absorbed into the tissue.2. The method of claim 1 , and further comprising inserting the flexible bioresorbable foam into a cavity or orifice of a living body to separate opposing tissue surfaces and prevent adhesion.3. The method of claim 2 , wherein the cavity is a nasal/sinus cavity claim 2 , otologic cavity claim 2 , a cranial cavity claim 2 , a thoracic cavity claim 2 , an abdominal cavity claim 2 , a pelvic cavity claim 2 , an eye cavity claim 2 , an ear cavity claim 2 , a nose cavity or a ...

Подробнее
Номер записи: 18
11-04-2013 дата публикации

SKIN-FRIENDLY ADHESIVES FROM POLYALKLETHER-BASED PHOTOINITIATORS

Номер: US20130089581A1
Автор: Madsen Niels Joergen, Nielsen Christian B.
Принадлежит: COLOPLAST A/S

The invention provides a method for manufacturing a skin-friendly pressure-sensitive adhesive composition, said method comprising the steps of: a. providing a matrix composition comprising a polymeric photoinitiator of the general formula (I): R(A)-(R(A)-0)-(R(A)n-O)—R4(A)(I) and b. curing the matrix composition in step a. by exposing it to UV radiation. The matrix composition may additionally comprise one or more adhesive-forming polymers and/or adhesive-forming monomers, or may simply consist of the polymeric photoinitiator of the general formula I, as defined herein. The invention also relates to the skin-friendly pressure-sensitive adhesive composition obtained by the method of the invention, as well as a medical device comprising said adhesive composition. 1. A method for manufacturing a skin-friendly pressure-sensitive adhesive composition , said method comprising the steps of: {'br': None, 'sub': 1', '1', 'r', '2', '2', 'm', 'o', '3', '3', 'n', 'p', '4', '4', 's, 'R(A)-(R(A)-O)—(R(A)-O)—R(A)\u2003\u2003(I)'}, 'a. providing a matrix composition comprising a polymeric photoinitiator of the general formula I{'sub': 2', '3', '2', '3', '2', '2', '1', '8', '3', '8', '1', '4', '1', '4', '2', '2', '1', '8', '3', '8, 'wherein Rand Rare independently at each occurrence identical or different, linear or branched alkylene or cycloalkylene groups; wherein Rand Rmay be substituted with one or more substituents selected from CN; azides, esters; ethers; amides; halogen atoms; sulfones; sulfonic derivatives; NHor Nalk, where alk is any C-Cstraight chain alkyl group, C-Cbranched or cyclic alkyl group; Rand Rare independently at each occurrence identical or different, linear or branched alkyl or cycloalkyl groups or aryl groups or are independently at each occurrence selected from H, OH, CN, halogens, amines, amides, alcohols, ethers, thioethers, sulfones and derivatives thereof, sulfonic acid and derivatives thereof, sulfoxides and derivatives thereof, carbonates, isocyanates, ...

Подробнее
Номер записи: 19
11-04-2013 дата публикации

CHITOSAN BEADS AND FILLER COMPRISING SUCH BEADS

Номер: US20130090306A1
Автор: Boderke Peter, Hauptmeier Bernhard, Kiehm Kevin
Принадлежит: Merz Pharma GmbH & Co. KGaA

The present invention pertains to chitosan beads consisting of chitosan cross-linked with citrate ions. The present invention furthermore pertains to a filler comprising such chitosan-citrate beads. In one embodiment of the instant invention the filler is a dermal filler. In one further embodiment of the present invention the dermal filler is for the treatment of wrinkles and/or folds. In another embodiment of the instant invention the filler is for use in the treatment of a medical condition. The filler provided in the present invention may further comprise one or more active pharmaceutical ingredients. Further, the present invention pertains to a process for preparing the filler as claimed herein. 115-. (canceled)16. Chitosan beads consisting essentially of chitosan and citrate ions.17. The chitosan beads of claim 16 , wherein the chitosan has an average molecular weight of from about 50 kD to about 5000 kD.18. The chitosan beads of claim 16 , wherein the chitosan is deacetylated to a degree of from about 70% to about 100%.19. The chitosan beads of claim 16 , wherein the chitosan beads exhibit a mass median diameter of less than or equal to 1500 μm as determined by microscopical analysis.20. The chitosan beads of claim 16 , wherein the mass median diameter of a chitosan bead remains less than or equal to 1500 μm for a period of 6 months at 25° C.±2° C. and 60%±5% relative humidity as determined by laser diffraction analysis.21. The chitosan beads of claim 16 , wherein the chitosan beads have a shelf-life of 6 months at 25° C.±2° C. and 60%±5% relative humidity.22. A filler comprising the chitosan beads of .23. The filler of claim 22 , further comprising (i) a polysaccharide claim 22 , and/or (ii) one or more active pharmaceutical ingredients selected from the group consisting of anesthetics claim 22 , analgesics claim 22 , anti-microbials claim 22 , anti-inflammatory drugs claim 22 , growth factors claim 22 , hormones claim 22 , cosmeceuticals claim 22 , vitamins ...

Подробнее
Номер записи: 20
25-04-2013 дата публикации

FUNCTIONALIZED ADHESIVE FOR MEDICAL DEVICES

Номер: US20130098550A1
Автор: Hadba Robert Ahmad, Sargeant Tim, Stopek Joshua
Принадлежит: COVIDIEN LP

A method for adhering a medical device to biological tissue includes adhering an adhesive composition having a plurality of reactive members of a specific binding pair to tissue which has a plurality of complementary reactive members of the specific binding pair via click chemistry. 1. A method for adhering a medical device to biological tissue comprising:providing a bifunctional adhesive composition having a plurality of reactive members of a first specific binding pair and a plurality of reactive members of a second specific binding pair;providing tissue with a plurality of complementary reactive members of the first specific binding pair;contacting the adhesive composition with the biological tissue, wherein upon contact of the reactive members of the first specific binding pair with the complimentary reactive members of the first specific binding pair associated with the tissue, covalent bonds are formed between the reactive members and the complementary reactive members of the first specific binding pair, thus adhering the adhesive to the tissue;providing a medical device having a plurality of complementary reactive members of the second specific binding pair;contacting the medical device with the adhesive, wherein upon contact of the reactive members of the second specific binding pair with the complimentary reactive members of the second specific binding pair associated with the device, covalent bonds are formed between the reactive members and the complementary reactive members of the second specific binding pair, thus adhering the device to the adhesive composition.2. The method for adhering a medical device to biological tissue according to wherein the members of the first specific binding pair bind to one another via a reaction selected from the group consisting of Huisgen cycloaddition reaction claim 1 , a Diels-Alder reaction and a thiol-ene reaction and the members of the second specific binding pair bind to one another via a reaction selected from the ...

Подробнее
Номер записи: 21
16-05-2013 дата публикации

Organophosphorous, Multivalent Metal Compounds, and Bioactive Glass Material Macromolecular Network Compositions and Methods

Номер: US20130122057A1
Автор: Garigapati Venkat R., Kimsey Cassandra L., Murphy Matthew E.
Принадлежит:

Cements containing certain small molecule amino acid phosphate compounds such as phosphoserine and certain multivalent metal compounds such as but not limited to calcium phosphate have been found to have improved properties and form a macromolecular network in the presence of a bioactive glass material that contain silicates, phosphates, and calcium salts which can be involved in the formation of bonding sites. 1. A bone restorative composition comprising a reactive mixture of a small amino acid phosphate species , a multivalent metal compound , and a bioactive glass material that contains ionic functional groups.3. The bone restorative composition of claim 1 , wherein the small amino acid phosphate species is present in an amount from about 10% to about 90% by weight claim 1 , preferably about 15% to about 50% by weight claim 1 , and more preferably about 20% to about 40% by weight claim 1 , based on the combined weight of the compound claim 1 , the multivalent metal compound claim 1 , and the bioactive glass material.4. The bone restorative composition of claim 1 , wherein the small amino acid phosphate species is phosphoserine.5. The bone restorative composition of claim 1 , wherein the multivalent metal compound is present in an amount from about 5% to about 90% by weight claim 1 , preferably about 40% to about 80% by weight claim 1 , and more preferably about 40% to about 65% by weight claim 1 , based on the combined weight of the small amino acid phosphate species claim 1 , the multivalent metal compound claim 1 , and the bioactive glass material.6. The bone restorative composition of claim 1 , wherein the multivalent metal compound is selected from the group consisting of tetracalcium phosphate claim 1 , calcium oxide claim 1 , calcium chloride claim 1 , or calcium hydroxide.7. The bone restorative composition of claim 1 , wherein multivalent metal compound has a mean particle size of greater than 15 μm claim 1 , preferably greater than 25 μm.8. The bone ...

Подробнее
Номер записи: 22
16-05-2013 дата публикации

TRANSDERMAL ADHESIVE COMPOSITIONS, DEVICES AND METHODS

Номер: US20130122079A1
Автор: DiZio James P., Johnson Elizabeth E., Preszier Prince Amy, Wu Zheng Zhi
Принадлежит:

A stable transdermal adhesive composition comprising: an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; and at least one pharmaceutically active compound which is susceptible to oxidative degradation; wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive, methods of making the composition, a transdermal drug delivery device using the composition, methods of making the device, and methods of delivery the pharmaceutically active compound are provided. 1. A transdermal adhesive composition comprising:an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; andat least one pharmaceutically active compound which is susceptible to oxidative degradation;wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive; andwherein any free radical initiator, if present in the adhesive, is present at a level of less than 20 ppm, based upon the total weight of the adhesive.2. A transdermal adhesive composition comprising:an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; and(S)—N-ethyl-N-methyl-3-[1-(dimethylamino)ethyl]phenyl carbamate or a pharmaceutically acceptable salt thereof;wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive.3. The composition of claim 2 , wherein any free radical initiator claim 2 , if present in the adhesive claim 2 , is present at a level of less than 20 ppm ...

Подробнее
Номер записи: 23
23-05-2013 дата публикации

INTRINSICALLY MAGNETIC HYDROXYAPATITE

Номер: US20130129634A1
Автор: Banobre Lopez Manuel, LANDI Elena, Marcacci Maurilio, Pressato Daniele, Rivas Rey Jose, SANDRI Monica, TAMPIERI Anna
Принадлежит:

The present invention relates to hydroxyapatite doped with Fe ions and Fe ions which partially substitute the calcium ions in the crystal lattice. The hydroxyapatite is characterized by an intrinsic magnetism of 0.05 to 8 emu/g, measured by applying a magnetic field of 34 Oe, due to the presence of magnetic nano-domains in the crystal lattice of HA, given the limited amount of magnetic secondary phases present, less than about 3% by volume. 1. A hydroxyapatite comprising calcium ions and phosphate ions in a crystal lattice , characterized in that it is doped with Fe ions and Fe ions , which partially substitute said calcium ions in said crystal lattice in a quantitative ratio Fe/Fe of 1 to 4 , has magnetism of 0.05 to 8 emu/g , measured by applying a magnetic field of 34 Oe , due to the presence of magnetic nano-domains in the lattice of hydroxyapatite , and comprises an amount of secondary magnetic phases below about 3 vol %.2. The hydroxyapatite according to claim 1 , wherein said magnetism is of 0.1 to 5 emu/g claim 1 , recorded by applying a magnetic field of 34 Oe.3. The hydroxyapatite according to or claim 1 , wherein said ratio Fe/Fe is of 2 to 3.5.4. The hydroxyapatite according to claim 1 , comprising an amount of secondary magnetic phases≦2 vol %.5. The hydroxyapatite according to claim 1 , having a ratio (Fe+Ca)/P of 1.5 to 1.9.6. The hydroxyapatite according to claim 1 , in the form of nanoparticles having a width of 5-10 nm to 20-30 nm and a length up to 80-150 nm claim 1 , or in the form of aggregates/granules of said nanoparticles.7. The hydroxyapatite according to claim 6 , wherein said nanoparticles comprise spherical voids of 2-5 nm.8. The hydroxyapatite according to claim 1 , loaded with biological substances selected in the group consisting of proteins claim 1 , genes claim 1 , stem cells claim 1 , growth factors and vascularization factors; or loaded with active substances or drugs.9. A biomimetic bone or osteocartilage substitute comprising a ...

Подробнее
Номер записи: 24
30-05-2013 дата публикации

NONAQUEOUS PRESSURE-SENSITIVE ADHESIVE FOR MEDICINAL TAPE PREPARATION FOR PERCUTANEOUS ABSORPTION, MEDICINAL TAPE PREPARATION FOR PERCUTANEOUS ABSORPTION, AND PROCESS FOR PRODUCING THE SAME

Номер: US20130138056A1
Автор: Kawamura Naohisa, Kobayashi Takayuki, SAWADA Hidenori
Принадлежит: NIPRO PATCH CO., LTD.

The present invention is directed to a nonaqueous pressure-sensitive adhesive that may be used in medicinal tape preparations for percutaneous absorption. The adhesive may comprise a copolymer obtained by copolymerization of a (meth)acrylic monomer having an acetoacetyl group in the molecule and one or more monomers from among other (meth)acrylic monomers without acetoacetyl groups and copolymerizable vinyl monomers, in a nonaqueous solvent. Suitable (meth)acrylic monomers having an acetoacetyl group in the molecule are acetoacetoxyalkyl methacrylates, and especially 2-acetoacetoxyethyl methacrylate. The pressure-sensitive adhesive of the invention uses no polyamine derivatives, isocyanate compounds, polyvalent metal chelate compounds, etc., as crosslinking agents, and therefore toxicity is not a concern and skin is not irritated. A medicinal tape preparation for percutaneous absorption of the invention has superior adhesive strength and cohesive strength, and is highly safe with low skin irritation. It also has excellent drug release and percutaneous absorption properties. 1. A non-aqueous pressure-sensitive adhesive for use in a medicinal tape preparation for percutaneous absorption , wherein the adhesive comprises a copolymer obtainable by copolymerization of (i) a (meth)acrylic monomer having an acetoacetyl group in the molecule and (ii) one or more monomers selected from the group consisting of (meth)acrylic monomers with no acetoacetyl group and copolymerizable vinyl monomers , in a non-aqueous solvent.2. The adhesive of claim 1 , wherein the (meth)acrylic monomer having an acetoacetyl group in the molecule is an acetoacetoxyalkyl(meth)acrylate.3. The adhesive of claim 1 , wherein the one or more monomers is selected from the group consisting of 2-ethylhexyl acrylate claim 1 , methyl methacrylate claim 1 , diacetoneacrylamide claim 1 , butyl acrylate claim 1 , ethyleneglycol dimethacrylate claim 1 , ethyleneglycol diacrylate claim 1 , diethyleneglycol ...

Подробнее
Номер записи: 25
06-06-2013 дата публикации

PRECURSOR COMPOSITION FOR CROSSLINKABLE PRESSURE-SENSITIVE ADHESIVE FOR SKIN

Номер: US20130143979A1
Автор: KAMIYAMA Fumio, Kawamura Naohisa, QUAN Ying Shu, SAWADA Hidenori
Принадлежит: NIPRO PATCH CO., LTD.

A composition for production of a crosslinkable pressure-sensitive adhesive for skin, obtained by dissolving in a solvent 100 parts by weight of an acrylic copolymer (copolymer A) comprising a (meth)acrylic acid alkyl ester as the main constituent component and 3-45 wt % diacetoneacrylamide as an essential constituent component, and containing no free carboxyl groups, and 0.1-30 parts by weight of an acrylic copolymer (copolymer B) comprising a (meth)acrylic acid alkyl ester as the main constituent component and a primary amino group and/or carboxyhydrazide group on a side chain, and containing no free carboxyl groups. 1. A precursor composition for a crosslinkable pressure-sensitive adhesive for skin , comprising:i) an acrylic copolymer (copolymer A) comprising a (meth)acrylic acid alkyl ester as the main constituent component and 3-45 wt % diacetone acrylamide as an essential constituent component, and containing no free carboxyl groups, andii) an acrylic copolymer (copolymer B) comprising a (meth)acrylic acid alkyl ester as the main constituent component and a primary amino group on a side chain, and containing no free carboxyl groups, wherein the primary amino group is present at a density of at least 2 per molecule of copolymer B and the primary amino group and/or carboxyhydrazide group in copolymer B is included at a density of one per 5-100 molecules of (meth)acrylic acid ester comonomer in copolymer B, wherein the molecular weight of copolymer B is at least 2000;wherein the proportion by weight of copolymer B with respect to polymer A is 0.1-30:100, and wherein copolymers A and B are dissolved in a solvent.2. A precursor composition according to claim 1 , wherein the solvent contains acetone and/or butanone claim 1 , and the amount of acetone and/or butanone is at least 5.0 wt % with respect to the total amount of solvent.3. A precursor composition according to claim 1 , wherein the solvent contains acetone and/or butanone claim 1 , and the amount of acetone ...

Подробнее
Номер записи: 26
13-06-2013 дата публикации

HYDROXYAPATITE TISSUE FILLER AND ITS PREPARATION AND USE

Номер: US20130149348A1
Автор: BEULING Nienke, BEZEMER Mariska, DE GROOT Klaas, VAN DE MORTEL Nol
Принадлежит: Cam Bioceramics B.V.

The invention pertains to a biocompatible composition, suitable for use in soft or hard tissue augmentation, wherein the composition is an aqueous suspension containing a carrier fraction of ceramic particles of less than μm and an augmentation fraction of ceramic particles of at least μm. The ceramics typically include calcium phosphate. The composition is a may be used in soft tissue repair as well as hard bone replacement. It advantageously avoids the need for foreign body materials which are conventionally applied to stabilize augmentation suspensions. 1. A biocompatible composition , suitable for use in soft or hard tissue augmentation , wherein the composition is an aqueous suspension containing a carrier fraction of ceramic particles of less than 15 μm and an augmentation fraction of ceramic particles of at least 20 μm.2. The composition according to claim 1 , wherein said ceramic particles comprise calcium phosphate.3. The composition according to claim 1 , wherein said carrier particles are smaller than 10 μm.4. The composition according to claim 3 , wherein said carrier particles are preferably 20-1000 nm.5. The composition according claim 1 , wherein more than 50% of the total volume of particles in said carrier fraction is in singular form.6. The composition according to claim 1 , wherein said carrier fraction comprises hydroxyapatite (HA) and/or tricalcium phosphate (TCP).7. The composition according to claim 1 , wherein the weight ratio of said augmentation fraction and said carrier fraction is 0.5:1 to 15:1.8. The composition according to claim 1 , wherein the composition is suitable for soft tissue augmentation claim 1 , said composition being injectable claim 1 , comprising augmentation particles of 20-100 μm and having a surface porosity of less than 30%.9. The composition according to claim 1 , wherein the composition is suitable for hard tissue augmentation claim 1 , said composition comprising augmentation particles of 100 μm to 4 mm and having ...

Подробнее
Номер записи: 27
20-06-2013 дата публикации

Paste-Like Bone Cement

Номер: US20130158158A1
Автор: VOGT Sebastian
Принадлежит: HERAEUS MEDICAL GMBH

The present invention relates to a kit comprising at least two pastes, A and B. Paste A contains at least one monomer for radical polymerisation; and at least one barbituric acid derivative as polymerisation initiator. Paste B contains at least one monomer for radical polymerisation; and at least one heavy metal compound as polymerisation accelerator that is selected from heavy metal salts and heavy metal complexes. Paste B contains less than 0.01% by weight, relative to the total weight of paste B, of a peroxide; at least one of the pastes A and B contains-at least one filling agent that is poorly soluble or insoluble in the monomer for radical polymerization in either paste A or B respectively; and at least one of the pastes A and B contains at least one inorganic halide salt. 1. A kit comprising a paste A and a paste B ,whereby (a1) at least one monomer for radical polymerisation; and', '(a2) at least one barbituric acid derivative as polymerisation initiator;, '(a) paste A comprises'} (b1) at least one monomer for radical polymerisation; and', '(b2) at least one heavy metal compound as polymerisation accelerator that is selected from the group consisting of heavy metal salts and heavy metal complexes;, '(b) paste B comprises'}whereini) paste B contains less than 0.01% by weight, relative to the total weight of paste B, of a peroxide;ii) at least one of the pastes A and B contains, as component (a3) and/or (b3), at least one filling agent that is insoluble or poorly soluble in (a1) and/or (b1), respectively; andiii) at least one of the pastes A and B contains at least one inorganic halide salt as component (a4) and/or (b4).2. The kit according to claim 1 , whereby the at least one monomer (a1) and/or (b1) for radical polymerisation is a methacrylate monomer.3. The kit according to wherein paste A and paste B contain an amount of the at least one monomer (a1) and/or (b1) for radical polymerisation in a range of 15 to 85% by weight claim 1 , each relative to the ...

Подробнее
Номер записи: 28
27-06-2013 дата публикации

Coupling an Ultrasound Probe to the Skin

Номер: US20130165005A1
Автор: Gjermund Fjeld Olsen, Nicolay Berard-Andersen
Принадлежит: NEORAD AS

A tape for securing an ultrasound probe to the skin may include a sonolucent silicone gel for transmitting ultrasound from an ultrasound transducer to the body. A method of manufacturing an adhesive silicone product may include a step of treating the adhesive composition or components of the composition to remove air or prevent the formation of air bubbles, in order to provide a sonolucent adhesive product.

Подробнее
Номер записи: 29
27-06-2013 дата публикации

BONDING TISSUES AND CROSS-LINKING PROTEINS WTH NAPHTHALIMIDE COMPOUNDS

Номер: US20130165970A1
Автор: Judy Millard M., Kloster Kaia L., Matthews James L., Utecht Ronald E., Vaska Kevin J.
Принадлежит: Alumend, LLC

Naphthalimide compounds are used in tissue bonding and protein cross-linking applications. When activated by an activating agent, such as light in the 400-500 nm absorption range, the naphthalimide compounds form chemically-reactive species that cross-link proteins, bond connective tissues together, and bond tissues and other biomaterials together. A naphthalimide-labeled biomolecule, such as a naphthalimide-labeled chitosan, is also capable of bonding tissues without subsequent direct illumination of the contacted tissue area. The naphthalimide compounds may be used in tissue or arterial repair, stabilization of an expanded arterial wall after angioplasty, tethering pharmaceutical agents to tissue surfaces to provide local drug delivery, and for chemically bonding skin care products, sunscreens, and cosmetics to the skin. 144.-. (canceled)45. A method of effecting wound closure of at least one tissue surface comprising:activating a compound having the formula D-B with a sufficient amount of an activating agent; andapplying the activated compound to the at least one tissue surface;wherein D is a naphthalimide compound and B is a biomolecule.46. The method of claim 45 , further comprising a step of compressing the at least one tissue surface to effect wound closure.47. The method of claim 45 , with the proviso that a further step of activation of the compound after application to the tissue surface is not needed.49. The method of claim 45 , wherein B is a biomolecule selected from the group consisting of chitosan claim 45 , protein claim 45 , hydrolyzed protein claim 45 , and carbohydrates. This application claims priority to U.S. Provisional Patent Application Ser. No. 60/517,618, entitled “BONDING TISSUES AND CROSS-LINKING PROTEINS WITH NAPHTHALIMIDE COMPOUNDS” filed on Nov. 5, 2003, having Ronald E. Utecht, Kaia L. Kloster, Millard M. Judy, Kevin J. Vaska, and James L. Matthews, listed as the inventor(s), the entire content of which is hereby incorporated by ...

Подробнее
Номер записи: 30
11-07-2013 дата публикации

AQUEOUS COMPOSITIONS AND METHODS FOR BONE HEMOSTASIS

Номер: US20130177601A1
Автор: Goessl Andreas, Gorna Katarzyna I., Gulle Heinz
Принадлежит:

Bone hemostat compositions, and methods for their use and manufacture are provided. Exemplary hemostatic compositions include polymeric components such as random and non-random copolymers, natural polymers, ceramics, reactive group polymers, and combinations thereof. Bone compositions may be used during surgical procedures, and may be applied to bone to inhibit or prevent bleeding from bone. 1. A biocompatible composition for use as a bone hemostat , the composition comprising:water; anda polyoxyethylene-polyoxypropylene block copolymer having a molecular weight (Mw) within a range from about 9800 Mw to about 16300 Mw.2. A biocompatible composition according to claim 1 , wherein the polyoxyethylene-polyoxypropylene block copolymer is a triblock copolymer.3. A biocompatible composition according to claim 1 , wherein the polyoxyethylene-polyoxypropylene block copolymer has a molecular weight (Mw) within a range from about 9800 Mw to about 14600 Mw.4. A biocompatible composition according to claim 1 , wherein the block copolymer comprises a percentage of polyethylene oxide within a range from about 60% to about 80%.5. A biocompatible composition according to claim 1 , wherein the block copolymer comprises a percentage of polypropylene oxide within a range from about 20% to about 40%.6. A biocompatible composition according to claim 1 , wherein the polyoxyethylene-polyoxypropylene block copolymer comprises 202 ethylene oxide units and 56 propylene oxide units.7. A biocompatible composition according to claim 1 , wherein:the water is present within a range from about 20% to about 45% by weight of the composition, andthe polyoxyethylene-polyoxypropylene block copolymer is present within a range from about 20% to about 80% by weight of the composition.8. A biocompatible composition according to claim 1 , further comprising a natural polymer selected from the group consisting of a gelatin claim 1 , chitosan claim 1 , and collagen.9. A biocompatible composition according to ...

Подробнее
Номер записи: 31
11-07-2013 дата публикации

THERAPEUTIC AGENT FOR PULMONARY EMPHYSEMA

Номер: US20130178426A1
Автор: Anzai Takao, Nogawa Atsuhiko, Tada Yuichi
Принадлежит: TERUMO KABUSHIKI KAISHA

The invention has as its object the provision of a medicine capable of reducing a volume of emphysema-suffering pulmonary alveoli or alveolar sacs by means of a respiratory region volume inhibitor containing a coating film formation as a main component and capable of forming a coating film in a respiratory region, characterized by being used in such a way that the coating film-forming component is administered to an emphysema-suffering pulmonary alveolar parenchyma in a human-respiratory region in an amount of 0.004 to 200 g/application, preferably 0.07 to 20 g/application and more preferably 0.5 to 5 g/application on each occasion. 1. A respiratory region volume inhibitor containing a coating film-forming component as a main component and capable of forming a coating film in a respiratory region ,being used in such a way that the coating film-forming component is administered to an emphysema-suffering pulmonary alveolar parenchyma in a human-respiratory region in an amount of 0.004 to 200 g on each occasion.2. The respiratory region volume inhibitor according to claim 1 ,wherein the coating film-forming component is configured such that a balloon-shaped closed pouch made of the coating film is formed in intimate contact with an inner surface of the respiratory region along an inner peripheral surface of the respiratory region in response to an external stimulation, andthe balloon-shaped closed pouch is shrunk by reducing a pressure inside the balloon-shaped closed pouch from outside of the respiratory region.3. The respiratory region volume inhibitor according to claim 2 ,wherein the external stimulation includes an external stimulation component.4. The respiratory region volume inhibitor according to claim 1 ,wherein the coating film-forming component contains a tacky polymer, andthe external stimulation component is made of a reactive gas.5. The respiratory region volume inhibitor according to claim 1 ,wherein the coating film-forming component contains polymer ...

Подробнее
Номер записи: 32
25-07-2013 дата публикации

CROSS-LINKED BIOACTIVE HYDROGEL MATRICES

Номер: US20130189371A1
Автор: Hill Ronald Stewart, Klann Richard Chris, Lamberti Francis Vincent
Принадлежит: PIONEER SURGICAL ORTHOBIOLOGICS, INC.

The present invention is directed to a stabilized cross-linked hydrogel matrix comprising a first high molecular weight component and a second high molecular weight component that are covalently linked, and at least one stabilizing or enhancing agent, wherein the first high molecular weight component and the second high molecular weight component are each selected from the group consisting of polyglycans and polypeptides. This stabilized hydrogel matrix may be prepared as bioactive gels, pastes, slurries, cell attachment scaffolds for implantable medical devices, and casting or binding materials suitable for the construction of medical devices. The intrinsic bioactivity of the hydrogel matrix makes it useful as a gel or paste in multiple applications, including as a cell attachment scaffold that promotes wound healing around an implanted device, as gels and pastes for induction of localized vasculogenesis, wound healing, tissue repair, and regeneration, as a wound adhesive, and for tissue bulking. 1. A bone implant material formed of a molded composition having a predetermined shape and comprising: a crosslinked bioactive hydrogel matrix comprising a polyglycan crosslinked to a polypeptide , and at least one enhancing agent selected from the group consisting of polar amino acids , intact collagen , divalent cation chelators , and combinations thereof; and an osteoinductive or osteoconductive material comprising hydroxyapatite.2. The bone implant material of claim 1 , wherein the polyglycan is a polysaccharide or a sulfated polysaccharide.3. The bone implant material of claim 2 , wherein the polyglycan is selected from the group consisting of glycosaminoglycans claim 2 , glucosaminoglycans claim 2 , dextran claim 2 , heparan claim 2 , heparin claim 2 , hyaluronic acid claim 2 , alginate claim 2 , agarose claim 2 , carageenan claim 2 , amylopectin claim 2 , amylose claim 2 , glycogen claim 2 , starch claim 2 , cellulose claim 2 , chitin claim 2 , heparan sulfate claim ...

Подробнее
Номер записи: 33
25-07-2013 дата публикации

Light Activated Composite Tissue Adhesives

Номер: US20130190245A1
Автор: Soltz Barbara A., Soltz Robert
Принадлежит:

A light activated collagen-flavin composite layer incorporating riboflavin is applied as treatment for infected lesions caused by bacteria and as the consequence of surgical procedures. These composites have also been found to be strong tissue adhesives that are effective in closing and sealing wounds, fixation of grafts/ implants and anastomoses. Advantages include speed of closure, reduced infection due to the elimination of foreign matter, evidence of accelerated wound healing and the ease of use in complex surgery, especially when watertight seals, limited access or small repair size are important factors. The riboflavin in the collagen layer is exposed to light (e.g., light having a wavelength between 360-375 nm or 440-480 nm), decomposing the riboflavin to form reactive oxygen species (ROS). Strong crosslinks between the collagen composite and tissue results. In addition, similar exposures eradicate pathogens in the wound is eradicated resulting in a sterile wound. In other examples, the composite film may instead contain lumichrome or lumiflavin. 1. A composition , comprising:gelatin, wherein a concentration of the gelatin in the composition is in a range of 20% (w/v) to 50% (w/v);collagen, wherein a concentration of the collagen in the composition is in a range of 10% to 40% (w/v); anda chromophore that produces a reactive oxygen species upon exposure to electromagnetic radiation.2. A composition in accordance with claim 1 , wherein the chromophore includes riboflavin.3. A composition in accordance with claim 1 , wherein a concentration of the riboflavin in the composition is within a range of 0.1% to 2.0% (w/v).4. A composition in accordance with claim 1 , wherein the concentration of the riboflavin in the composition is substantially equal to 1.0%.51. A composition in accordance claim 1 , wherein the chromophore includes lumiflavin.6. A composition in accordance with claim 1 , wherein the chromophore includes lumichrome.7. A composition in accordance with ...

Подробнее
Номер записи: 34
01-08-2013 дата публикации

LOW SWELL, LONG-LIVED HYDROGEL SEALANT

Номер: US20130195789A1
Автор: Lu Helen S.M.
Принадлежит: ACTAMAX SURGICAL MATERIALS LLC

A low swell, long-lived hydrogel sealant formed by reacting a highly oxidized polysaccharide containing aldehyde groups with a multi-arm amine is described. The hydrogel sealant may be particularly suitable for applications requiring low swell and slow degradation, for example, ophthalmic applications such as sealing wounds resulting from trauma such as corneal lacerations, or from surgical procedures such as vitrectomy procedures, cataract surgery, LASIK surgery, glaucoma surgery, and corneal transplants; neurosurgery applications, such as sealing the dura; and as a plug to seal a fistula or the punctum. The low swell, long-lived hydrogel sealant may also be useful as a tissue sealant and adhesive, and as an anti-adhesion barrier. 1. A method for applying a low swell , degradable hydrogel to an anatomical site on tissue of a living organism comprising applying to the site (a) a first aqueous solution or dispersion comprising at least one highly oxidized polysaccharide containing aldehyde groups , said highly oxidized polysaccharide having a weight-average molecular weight of about 1 ,000 to about 1 ,000 ,000 Daltons and an equivalent weight per aldehyde group of about 65 to about 85 Daltons , wherein said first aqueous solution or dispersion contains said highly oxidized polysaccharide at a concentration of 6% to about 20% by weight; followed by (b) a second aqueous solution or dispersion comprising at least one water-dispersible , multi-arm amine wherein at least three of the arms are terminated by at least one primary amine group , said multi-arm amine having a number-average molecular weight of about 450 to about 200 ,000 Daltons , wherein said second aqueous solution or dispersion contains said multi-arm amine at a concentration of about 5% to about 30% by weight and mixing (a) and (b) on the site , or applying (b) followed by (a) and mixing (a) and (b) on the site , or premixing (a) and (b) to form a mixture and applying the mixture to the site; wherein a low ...

Подробнее
Номер записи: 35
01-08-2013 дата публикации

FILLER COMPOSITION COMPRISING BETA-GLUCANS

Номер: US20130196944A1
Автор: Barg Heiko
Принадлежит: Merz Pharma GmbH & Co. KGaA

The present invention pertains to a filler composition comprising β-glucan moieties and optionally a cosmetically and/or pharmaceutically acceptable carrier. It further relates to a filler composition, wherein the β-glucan moieties are cross-linked. in one embodiment of the instant invention the filler composition is a dermal filler. In one further embodiment of the present invention the filler composition is for the treatment of wrinkles and/or folds. In another embodiment of the instant invention the filler composition is for use in the treatment of a medical condition. The filler composition provided in the present invention may further comprise one or more active pharmaceutical ingredients. Further, the present invention pertains to a process for preparing the filler composition as claimed herein. 115-. (canceled)16. A filler composition comprising β-glucan moieties and , optionally , a cosmetically and/or pharmaceutically acceptable carrier , wherein the β-glucan moieties are cross-linked , and wherein the cross-linked β-glucan moieties form a monophasic gel.17. The filler composition of claim 16 , wherein the β-glucan moieties are selected from the group consisting of branched and unbranched β-glucan moieties claim 16 , β-(1 claim 16 ,3)-glucan claim 16 , β-(1 claim 16 ,4)-glucan claim 16 , β-(1 claim 16 ,3)-(1 claim 16 ,4)-glucan claim 16 , β-(1 claim 16 ,3)-(1 claim 16 ,6)-glucan and β-(1 claim 16 ,4)-(1 claim 16 ,6)-glucan moieties.18. The filler composition of claim 16 , wherein the β-glucan moieties are selected from the group consisting of cellulose claim 16 , chitin claim 16 , chitosan claim 16 , curdlan claim 16 , laminarin claim 16 , chrysolaminarin claim 16 , lentil pan claim 16 , lichenin claim 16 , plea ran claim 16 , zymosan claim 16 , schizophyllan claim 16 , scieroglucan claim 16 , β-glucans extracted from grain claim 16 , and any β-glucans produced by biotechnological means.19. The filler composition of claim 18 , wherein the grain is oat or ...

Подробнее
Номер записи: 36
15-08-2013 дата публикации

Synthesis of Amorphous Calcium Phosphate or Poorly Crystalline Calcium Phosphate Powders by Using Ca Metal

Номер: US20130209377A1
Автор: Ahmet Cuneyt Tas
Принадлежит: Individual

The present invention relates to the synthesis of bioceramics, in particular, of amorphous or cryptocrystalline calcium phosphates.

Подробнее
Номер записи: 37
15-08-2013 дата публикации

PEPTIDE HAVING THE ABILITY TO REGENERATE BONE TISSUE AND FOR BINDING TO APATITE

Номер: US20130210736A1
Автор: Chung Chong-Pyoung, Lee Jue- Yeon, Park Yoon-Jeong, Rhee Sang Hoon
Принадлежит: NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO., LTD.

The present invention relates to a peptide having bone tissue regeneration capacity and binding to surface of apatite, and more particularly, to a peptide having bone tissue regeneration capacity and specifically binding to a surface of apatite mineral, capable of being stably immobilized to the surface of apatite mineral to retain effective activity and exhibit bone regeneration effects for a long time, by linking an amino acid sequence having bone tissue regeneration capacity and an amino acid sequence having apatite-binding capacity to each other to thereby provide a peptide having both bone-forming effects and binding capacity to the surface of apatite mineral, and a composition for bone tissue regeneration, containing the peptide. The peptide having binding capacity to the apatite mineral and bone tissue regeneration capacity according to the present invention binds to the surface of apatite to thereby be present in a stable state, and thus can be used in a bone replacement material for dental or orthopedic application, and metal, natural polymers, or synthetic polymers, coated with apatite; promote transition, proliferation, and differentiation of cells associated with regeneration and eventually maximize bone tissue regeneration; and can be stably present while maintaining peptide activity when being grafted into the body and thus is useful in development of the bone tissue regeneration therapeutic technology using the peptide. 1. A peptide having bone tissue regeneration capacity and binding to apatite , in which at least one peptide selected from the group consisting of amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 35 and at least one peptide selected from the group consisting of amino acid sequences of SEQ ID NO: 36 to SEQ ID NO: 39 are linked to each other.2. A peptide having bone tissue regeneration capacity and binding to apatite , wherein the peptide is represented by an amino acid sequence of SEQ ID NO: 40.3. A bone graft material in which the ...

Подробнее
Номер записи: 38
22-08-2013 дата публикации

THREE-DIMENSIONAL BONE IMPLANT AND METHOD FOR PRODUCING SAME

Номер: US20130216601A1
Автор: Rosenberg Orit
Принадлежит: Sheltagen Medical LTD.

A method for ex vivo production of a three-dimensional bone implant adapted for implantation to a patient, implants produced by such a method, and uses of such implants. The method comprises disposing differentiated osteoblasts on a matrix support comprising at least one of collagen, calcium phosphate, calcium sulfate and tricalcium phosphate; contacting the differentiated osteoblasts on the matrix with autologous blood serum from the patient, comprising at least one of a growth factor and a cytokine; and disposing the differentiated osteoblasts on the matrix support and the medium in a bioreactor, in which production of the bone implant is performed. 1. A method for ex vivo production of a three-dimensional bone implant adapted for implantation to a patient , the method comprising:providing a matrix support comprising at least one selected from the group consisting of collagen, calcium phosphate tricalcium phosphate, and calcium sulfate;providing differentiated osteoblasts disposed on said matrix support;providing autologous blood serum from the patient, said serum comprising at least one of a growth factor and a cytokine;contacting said differentiated osteoblasts on said matrix support to medium comprising said autologous blood serum;disposing said differentiated osteoblasts on said matrix support and said medium within a bioreactor; andproducing the implant within said bioreactor.2. The method of claim 1 , wherein said growth factor is selected from the group consisting of a bone morphogenetic protein claim 1 , an insulin growth factor claim 1 , vascular endothelial growth factor claim 1 , platelet-derived growth factor claim 1 , and fibroblast growth factor.3. The method of claim 1 , further comprising exposing said differentiated osteoblasts on said matrix support to infrasonic mechanical stimulation.4. The method of claim 3 , wherein a frequency of said infrasonic mechanical stimulation is in the range of from about 4 Hz to about 60 Hz and a displacement ...

Подробнее
Номер записи: 39
22-08-2013 дата публикации

Compositions Comprising Bioadhesives And Methods Of Making The Same

Номер: US20130217790A1
Автор: Mehdizadeh Mohammadreza, Yang Jian
Принадлежит: The Board of Regents, The University of Texas System

In one aspect, compositions are described herein. In some embodiments, a composition comprises a polymer or oligomer formed from one or more polycarboxylic acids, one or more alcohols, and one or more catechol-containing species. In another aspect, methods of making a composition are described herein. In some embodiments, a method of making a composition comprises providing a polycarboxylic acid; providing an alcohol; combining the polycarboxylic acid with the alcohol; adding a catechol-containing species to the combination of the polycarboxylic acid and the alcohol; and forming a polymer or oligomer from the polycarboxylic acid, the alcohol, and the catechol-containing species. In some embodiments, the catechol-containing species comprises an amine moiety, a carboxylic acid moiety, or a hydroxyl moiety that is not part of the catechol group. 2. The composition of claim 1 , wherein a monomer of Formula (C) comprises dopamine or L-DOPA.4. The composition of claim 1 , wherein the polymer or oligomer is water soluble.5. The composition of claim 1 , wherein the polymer or oligomer is crosslinked to form a polymer network.6. The composition of further comprising a particulate material mixed with the polymer or oligomer.7. The composition of further comprising a drug mixed with the polymer or oligomer.8. The composition of claim 7 , wherein the polymer or oligomer is in nanoparticulate form.9. The composition of claim 1 , wherein the polymer or oligomer is bonded to a surface.10. A method of making a composition comprising:providing a polycarboxylic acid;providing an alcohol;combining the polycarboxylic acid with the alcohol;adding a catechol-containing species to the combination of the polycarboxylic acid and the alcohol, the catechol-containing species comprising an amine moiety, a carboxylic acid moiety, or a hydroxyl moiety that is not part of the catechol group; andforming a polymer or oligomer from the polycarboxylic acid, the alcohol, and the catechol-containing ...

Подробнее
Номер записи: 40
29-08-2013 дата публикации

CALCIUM PHOSPHATE COMPOSITION AND PROCESS FOR PRODUCTION THEREOF

Номер: US20130224263A1
Автор: HASHIMOTO Tadashi, Okada Koichi
Принадлежит:

A calcium phosphate composition comprising calcium phosphate particles (A) and a sulfonic acid salt (B), wherein the calcium phosphate composition contains 0.5 to 20 parts by weight of the sulfonic acid salt (B) based on 100 parts by weight of the calcium phosphate particles (A). This provides a calcium phosphate composition that has a time between the addition of a liquid agent to the calcium phosphate composition and the completion of setting in the use at a clinical site and the like, i.e., a setting time which is within an appropriate range and that is high in mechanical strength and good in marginal sealing ability. 125-. (canceled)26. A method of filling or applying a calcium phosphate composition paste to a substrate , comprising:producing a calcium phosphate composition powder comprising 0.5 to 20 parts by weight of a polysulfonic acid salt (B) based on 100 parts by weight of calcium phosphate particles (A) by mixing the calcium phosphate particles (A) and the polysulfonic acid salt (B) in the form of a powder;producing a calcium phosphate composition paste by adding a liquid comprising water as a main component to the calcium phosphate composition powder, followed by kneading; and thenfilling or applying the calcium phosphate composition paste to a desired site.27. The method of claim 26 , wherein the polysulfonic acid salt is a polystyrenesulfonic acid salt and/or a polyvinylsulfonic acid salt.28. The method of claim 26 , wherein the calcium phosphate composition powder further comprises an alkali metal salt of phosphoric acid (C).29. The method of claim 28 , wherein the alkali metal salt of phosphoric acid (C) is disodium hydrogen phosphate and/or sodium dihydrogen phosphate.30. The method of claim 26 , wherein the calcium phosphate particles (A) comprise tetracalcium phosphate particles (A1) and acidic calcium phosphate particles (A2).31. The method of claim 30 , wherein a blending ratio (A1/A2) of the tetracalcium phosphate particles (A1) to the acidic ...

Подробнее
Номер записи: 41
05-09-2013 дата публикации

WOUND HEALING COMPOSITIONS AND ASSOCIATED METHODS

Номер: US20130230566A1
Автор: Jr. Cary Jake, Lambert, Slaughter Thomas
Принадлежит:

In one embodiment, the present disclosure provides a composition including an aqueous solution comprising about 1% to about 50% weight/volume poloxamer having the general formula HO(CHO)(CHO)(CHO)H, wherein a ranges from 12-101 and b ranges from 20-56, and a substrate. In another embodiment, the present disclosure provides a method of attaching a substrate to a tissue by applying a substrate to a tissue and applying an aqueous solution comprising a poloxamer to the tissue in an amount sufficient for the poloxamer to hold the substrate to the tissue. In a third embodiment, the present disclosure a method of facilitating wound closure by applying an original substrate to a wound, applying an original aqueous solution comprising a poloxamer to the wound in an amount sufficient for the poloxamer to hold the substrate to the wound, and maintaining a substrate and poloxamer on the wound until wound closure. 1. A method of attaching a substrate to a tissue comprising:applying a substrate to a tissue; and{'sub': 2', '4', 'a', '3', '6', 'b', '2', '4', 'a, 'applying an aqueous solution comprising about 1% to about 50% weight/volume poloxamer having the general formula HO(CHO)(CHO)(CHO)H, wherein a ranges from 12-101 and b ranges from 20-56, to the tissue in an amount sufficient for the poloxamer to hold the substrate to the tissue.'}2. The method according to further comprising impregnating the substrate with the aqueous solution.3. The method according to claim 1 , further comprising applying the aqueous solution at a temperature at which the poloxamer is in the form of micelles claim 1 , than allowing the poloxamer to reach a temperature at which it forms hexagonal-packed cylinders.4. A method of facilitating wound closure comprising:applying an original substrate to a wound;{'sub': 2', '4', 'a', '3', '6', 'b', '2', '4', 'a, 'applying an original aqueous solution comprising about 1% to about 50% weight/volume poloxamer having the general formula HO(CHO)(CHO)(CHO)H, wherein ...

Подробнее
Номер записи: 42
19-09-2013 дата публикации

High Adhesion Antimicrobial Skin Prep Solution and Related Methods

Номер: US20130239977A1
Автор: JR. James E., McGuire
Принадлежит: entrotech life sciences, inc.

Antimicrobial skin prep solutions of the invention comprise: a major amount of at least one organic solvent, wherein at least about 80% by weight based on total weight of the solvent comprises at least one fugitive organic solvent; an antimicrobially effective amount of at least one antimicrobial agent; and an amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution, wherein the at least one adhesive is distinct from the at least one antimicrobial agent and is a liquid at room temperature. Coated substrates, applicators, and related methods are also disclosed. 1. An antimicrobial skin prep solution comprising:a major amount of at least one organic solvent, wherein at least about 80% by weight based on total weight of the solvent comprises at least one fugitive organic solvent;an antimicrobially effective amount of at least one antimicrobial agent; andan amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution,wherein the at least one adhesive is distinct from the at least one antimicrobial agent and is a liquid at room temperature.2. The antimicrobial skin prep solution of claim 1 , wherein the amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution is about 2% by weight of the skin prep solution.3. The antimicrobial skin prep solution of claim 1 , wherein the amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution is about 5.5% by weight of the skin prep solution.4. The antimicrobial skin prep solution of claim 1 , wherein the at least one adhesive is a hydrogel in the skin prep solution.5. The antimicrobial skin prep solution of claim 1 , wherein the ...

Подробнее
Номер записи: 43
19-09-2013 дата публикации

CALCIUM-CONTAINING STRUCTURES AND METHODS OF MAKING AND USING THE SAME

Номер: US20130243737A1
Автор: Starling L. Brian, Stephan James E.
Принадлежит: CAP BIOTECHNOLOGY INC

The present invention generally relates to calcium-containing structures and methods of making and using the structures. In one aspect, hollow calcium containing microstructures are used in conjunction with bone tissues/by-products to augment bone defects and extend the supply of bone tissues/by-products for bone augmentation. Bonding agents, such as calcium cements, are also used in the preparation of the hollow calcium microstructures combined with bone tissues/by-products or for use in preparing the hollow microstructures. The calcium-containing microstructures of the present invention are also useful as delivery vehicles of nitric oxide and/or nitric oxide containing or producing compounds for a variety of in vitro and in vivo uses. Calcium containing contoured substrates upon which cells/tissues can be grown in vitro for replacement and repair of tissues in vivo that conform in size and shape to the tissue surface to be replaced are also provided. 132.-. (canceled)33. A method of making a calcium-containing substrate , comprising the steps of:(a) obtaining a composition comprising calcium phosphate;(b) contouring said composition into a desired shape to form a contoured composition;(c) culturing cells or tissues onto the contoured composition to form the calcium-containing substrate.34. The method of claim 33 , further comprising the steps of:(d) removing the cultured cells or tissues from the contoured composition; and(e) transplanting the cultured cells or tissues into a patient in need thereof.35. The method of claim 33 , further comprising the step of transplanting the calcium-containing substrate into a patient in need thereof.36. The method of claim 33 , wherein calcium phosphate is hydroxylapatite claim 33 , tribasic calcium phosphate claim 33 , dicalcium phosphate claim 33 , tetracalcium phosphate claim 33 , calcium carbonate claim 33 , calcium oxide claim 33 , glass-containing calcium phosphate claim 33 , or a mixture thereof.37. The method of claim 33 ...

Подробнее
Номер записи: 44
26-09-2013 дата публикации

Modified Starch Material of Biocompatible Hemostasis

Номер: US20130251996A1
Автор: Chen Jianping, Ji Xin, Shi Xueshen, Xing Cheng
Принадлежит:

A modified starch material is arranged for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal. 1. A biocompatible modified starch , which is a pre-gelatinized starch product having water absorbency capacity not lower than 1 time its own particle weight.2. The biocompatible modified starch claim 1 , as recited in claim 1 , which is used for hemostasis claim 1 , adhesion prevention claim 1 , tissue healing promotion claim 1 , wound sealing claim 1 , and wounded tissue bonding in surgical operation and trauma treatment.3. The biocompatible modified starch claim 2 , as recited in claim 2 , which has a molecular weight 10 claim 2 ,000-2 claim 2 ,000 claim 2 ,000 Daltons or more and a grain diameter of 10 to 1000 μm.4. The biocompatible modified starch claim 3 , as recited in claim 3 , wherein the starch product is in form of hemostatic powder which has starch grains with grain diameter of 30˜500 μm claim 3 , wherein at least 95% starch grains in said hemostatic powder with a diameter of 30˜500 μm in total.5. The biocompatible modified starch claim 2 , as recited in claim 2 , which contains one or more groups of pre-gelatinized starch claim 2 , ...

Подробнее
Номер записи: 45
03-10-2013 дата публикации

LOW SWELL, LONG-LIVED HYDROGEL SEALANT

Номер: US20130255538A1
Автор: Lu Helen S.M.
Принадлежит:

A low swell, long-lived hydrogel sealant formed by reacting a highly oxidized polysaccharide containing aldehyde groups with a multi-arm amine is described. The hydrogel sealant may be particularly suitable for applications requiring low swell and slow degradation, for example, ophthalmic applications such as sealing wounds resulting from trauma such as corneal lacerations, or from surgical procedures such as vitrectomy procedures, cataract surgery, LASIK surgery, glaucoma surgery, and corneal transplants; neurosurgery applications, such as sealing the dura; and as a plug to seal a fistula or the punctum. The low swell, long-lived hydrogel sealant may also be useful as a tissue sealant and adhesive, and as an anti-adhesion barrier. 1. A dried hydrogel formed by a process comprising the steps of:a) combining (i) a first solution or dispersion comprising at least one highly oxidized polysaccharide containing aldehyde groups in a first solvent, said oxidized polysaccharide having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons and an equivalent weight per aldehyde group of about 65 to about 85 Daltons, wherein said first solution or dispersion contains said highly oxidized polysaccharide at a concentration of 6% to about 40% by weight; with (ii) a second solution or dispersion comprising at least one water-dispersible, multi-arm amine in a second solvent, wherein at least three of the arms of said multi-arm amine are terminated by at least one primary amine group, said multi-arm amine having a number-average molecular weight of about 450 to about 200,000 Daltons, wherein said second solution or dispersion contains said multi-arm amine at a concentration of about 5% to about 70% by weight, to form a hydrogel, wherein the first solvent is either the same as or different from the second solvent; andb) treating the hydrogel to remove at least a portion of said first solvent and said second solvent to form the dried hydrogel;provided that:(i) if ...

Подробнее
Номер записи: 46
03-10-2013 дата публикации

ADHESIVE FOR USE ON SKIN

Номер: US20130260134A1
Автор: Contrada Svetlana I
Принадлежит:

An adhesive for use on skin comprises acid-functionalized polyacrylate, one or more polyvinylpyrrolidones, and a low softening point resin. 1. An adhesive comprising:an acid-functionalized polyacrylate, one or more polyvinylpyrrolidones, and a low softening point resin.2. The adhesive of claim 1 , wherein the polyacrylate comprises monomers of acrylic acid and acrylic or meth(acrylic) esters.3. The adhesive of claim 2 , wherein the polyacrylate is present in about 60% to 94% by weight claim 2 , the one or more polyvinylpyrrolidones are present in about 3% to 20% by weight claim 2 , and the low softening point resin is present in about 5% to 20% by weight.4. The adhesive of claim 3 , wherein the polyacrylate is present in about 70% to 80% by weight.5. The adhesive of claim 3 , wherein the one or more polyvinylpyrrolidones are present in about 5% to 10% by weight6. The adhesive of claim 5 , wherein the adhesive comprises one polyvinylpyrrolidone.7. The adhesive of claim 6 , wherein the wherein the polyvinylpyrrolidone has a molecular weight of about 2 claim 6 ,000 g/mol to 3 claim 6 ,000 g/mol.8. The adhesive of claim 6 , wherein the wherein the polyvinylpyrrolidone has a molecular weight of about 28 claim 6 ,000 g/mol to 34 claim 6 ,000 g/mol.9. The adhesive of claim 6 , wherein the wherein the polyvinylpyrrolidone has a molecular weight of about 1 claim 6 ,000 claim 6 ,000 g/mol to 1 claim 6 ,500 claim 6 ,000 g/mol.10. The adhesive of claim 5 , wherein the adhesive comprises more than one polyvinylpyrrolidone.11. The adhesive of claim 3 , wherein the low softening point resin is a copolymer of acrylamide and ethylhexyl acrylate.12. The adhesive of claim 3 , wherein the adhesive at about a 2 mil thickness has an adhesion value to steel between about 0.2 lb/linear inch and 4.0 lb/linear inch.13. The adhesive of claim 3 , wherein the adhesive at about a 2 mil thickness has an adhesion value to polypropylene between about 0.2 lb/linear inch and 1.5 lb/linear inch.14. ...

Подробнее
Номер записи: 47
03-10-2013 дата публикации

HYDROGEL TISSUE ADHESIVE FOR MEDICAL USE

Номер: US20130261080A1
Автор: Lu Helen S.M., Shuey Steven W.
Принадлежит: ACTAMAX SURGICAL MATERIALS LLC

A hydrogel tissue adhesive formed by reacting an aldehyde-functionalized polysaccharide containing pendant aldehyde groups with a water-dispersible, multi-arm amine is described. The hydrogel may be useful as a tissue adhesive or sealant for medical applications that require a more rapid degradation time, such as the prevention of undesired tissue-to tissue adhesions resulting from trauma or surgery. 1. A method for applying a coating to an anatomical site on tissue of a living organism comprising the steps of applying to the sitea) at least one aldehyde-functionalized polysaccharide containing pendant aldehyde groups, said aldehyde-functionalized polysaccharide having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons and a degree of aldehyde substitution of about 10% to about 200%; followed byb) at least one water-dispersible, multi-arm amine wherein at least three of the arms are terminated by at least one primary amine group, said multi-arm amine having a number-average molecular weight of about 450 to about 200,000 Daltons, or (b) followed by (a), or premixing (a) and (b) and applying the resulting mixture to the site before the resulting mixture completely cures.2. The method according to wherein the aldehyde-functionalized polysaccharide is selected from the group consisting of aldehyde-functionalized derivatives of: dextran claim 1 , carboxymethyldextran claim 1 , starch claim 1 , agar claim 1 , cellulose claim 1 , hydroxyethylcellulose claim 1 , carboxymethylcellulose claim 1 , pullulan claim 1 , inulin claim 1 , levan claim 1 , and hyaluronic acid.3. The method according to wherein the water-dispersible claim 1 , multi-arm amine is selected from the group consisting of water-dispersible multi-arm polyether amines claim 1 , amino-terminated dendritic polyamidoamines claim 1 , and multi-arm branched end amines. This application is a divisional application of U.S. patent application Ser. No. 13/379,843, Filed Dec. 21, 2011 and U.S. ...

Подробнее
Номер записи: 48
03-10-2013 дата публикации

Medical absorbable hemostatic material for bone wounds and preparation method therefor

Номер: US20130261192A1
Автор: Fei XING, Nan Shen, Peng Yang, Xiangrui SONG
Принадлежит: GUANGZHOU ORTUS PHARMACEUTICAL TECHNOLOGY Co Ltd, GUANGZHOU ORTUS PHARMACEUTICAL TECHOLOGY Ltd

A medical absorbable hemostatic and wound healing promoting material for bone wounds and a preparation method thereof. The absorbable hemostatic material for bone wounds is formed of 40-95% of a base material and 5-60% of an adjuvant, based on weight percent, wherein the base material is an oligosaccharide, a polysaccharide, or a mixture of the oligosaccharide and the polysaccharide, and the adjuvant includes (1) one or more polyhydric alcohols, (2) one or more vegetable oils, and (3) one or more emulsifying agents. The method for preparing the absorbable hemostatic and wound healing promoting material for bone wounds comprises mixing a base material and an adjuvant at prescribed amounts by chemical blending or latex blending, cooling to form a solid lump, packaging, and sterilizing.

Подробнее
Номер записи: 49
03-10-2013 дата публикации

Methods, Materials and Apparatus for Treating Bone and Other Tissue

Номер: US20130261217A1
Автор: BEYAR Mordechay, GLOBERMAN Oren, Shavit Ronen, Wachsler-Avrahami Hila
Принадлежит: DePuy Spine, Inc.

A bone cement comprising a first component and a second component, wherein contacting the first component and the second component produces a mixture which attains a high viscosity an initial period and the viscosity of the mixture remains relatively stable for a working time of at least 5 minutes after the initial setting period, and the mixture is suitable for in-vivo use. 1. A bone cement comprising:a first component; anda second component,wherein, contacting the first component and the second component produces a mixture which attains a viscosity greater than 500 Pascal seconds within an initial period,wherein the viscosity of the mixture remains between 500 and 2000 Pascal seconds for a working time of at least 5 minutes after the initial period, andwherein the mixture is suitable for in-vivo use.2. The bone cement of claim 1 , wherein the working time is at least 8 minutes long.3. The bone cement of claim 1 , wherein the initial period is less than 3 minutes.4. The bone cement of claim 1 , wherein the initial period does not exceed 1 minute.5. The bone cement of claim 1 , wherein the mixture solidifies after the working time.6. The bone cement of claim 1 , wherein the initial period is less than 3 minutes and the mixture solidifies after the working time7. The bone cement of claim 6 , wherein the first component includes PMMA and Barium Sulfate.8. The bone cement of claim 6 , wherein the second component includes MMA and DMPT.9. The bone cement of claim 6 , wherein the first component includes PMMA claim 6 , Barium 30 Sulfate claim 6 , and Benzoyl Peroxide claim 6 , and wherein the second component includes MMA claim 6 , DMPT claim 6 , and Hydroquinone.10. The bone cement of claim 1 , wherein the viscosity of greater than 500 Pascal-second results at least partly from a polymerization reaction.11. A bone cement comprising:a first component; anda second component,wherein, contacting the first component and the second component produces a mixture which attains a ...

Подробнее
Номер записи: 50
10-10-2013 дата публикации

POST IRRADIATION SHELF-STABLE DUAL PASTE DIRECT INJECTABLE BONE CEMENT PRECURSOR SYSTEMS AND METHODS OF MAKING SAME

Номер: US20130264244A1
Автор: "OMahony Donal", Garigapati Venkat R., Hess Brian, Murphy Matthew E., Sun Wai Adrian
Принадлежит:

The present invention relates to a bone cement precursor system that is presented in the form of two shelf-stable pastes which have been terminally sterilized and are held in separate containers during product transport and storage. When the product is used during surgery, these pastes inject to a site of application through a static mixing device by the action of applied injection force. When the two pastes are mixed, they start to react to each other while injecting out. The resulting composition is highly biocompatible, osteoconductive, injectable, rapid setting and bioresorbable, and is useful in connection with bone repair procedures, for example, in the craniomaxillofacial, trauma and orthopedic areas. 1. A bone cement precursor system comprising:a first container containing an acidic aqueous paste comprising monocalcium phosphate monohydrate (MCPM) and dicalcium phosphate anhydrous (DCPA), citric acid, water, glycerol, polyvinyl pyrrolidone (PVP) and polyethylene glycol (PEG), anda second container containing an alkaline non-aqueous paste comprising at least one basic calcium phosphate mineral, at least one paste stabilizing agent, a surfactant and a solvent.2. The bone cement precursor system of claim 1 , wherein said system is shelf-stable post terminal sterilization.3. The bone cement of claim 2 , wherein said terminal sterilization is gamma irradiation.4. The bone cement precursor system of claim 1 , wherein the mean particle size of said monocalcium phosphate monohydrate (MCPM) and dicalcium phosphate anhydrous (DCPA) is between about 1 μm to about 90 μm.5. The bone cement precursor system of claim 1 , wherein the amount of said monocalcium phosphate monohydrate (MCPM) and dicalcium phosphate anhydrous (DCPA) present in said acidic aqueous paste is between about 5% w/w to about 65% w/w based on the total weight of said acidic aqueous paste.6. The bone cement precursor system of claim 4 , wherein the mean particle size of said monocalcium phosphate ...

Подробнее
Номер записи: 51
10-10-2013 дата публикации

Methods of building a body portion

Номер: US20130267026A1
Автор: Peter M. Bonutti
Принадлежит: P Tech LLC

An improved method of implanting cells in the body of a patient includes positioning viable cells on a support structure. One or more blood vessels may be connected with the support structure to provide a flow of blood through the support structure. A support structure may be positioned at any desired location in a patient's body. The support structure may be configured to replace an entire organ or a portion of an organ. An organ or portion of an organ may be removed from a body cells and/or other tissue is removed to leave a collagen matrix support structure having a configuration corresponding to the configuration of the organ or portion of an organ. Alternatively, a synthetic support structure may be formed. The synthetic support structure may have a configuration corresponding to a configuration of an entire organ or only a portion of an organ.

Подробнее
Номер записи: 52
10-10-2013 дата публикации

BONE SUBSTITUTE COMPOSITION

Номер: US20130268088A1
Автор: LIDGREN Lars, Nilsson Malin
Принадлежит: Bone Support AB

An injectable bone mineral substitute material composition with the capability of being hardened in a body fluid in vivo, which comprises at least one calcium phosphate component and at least one calcium sulfate component as a dry mixture mixed with an aqueous liquid, and at least one accelerator, the at least one calcium sulfate component being particulate hardened calcium sulfate, which has a specified particle size that is in order to confer injectablity to the composition. The invention also concerns the bone mineral substitute material produced from the composition as well as methods and uses thereof. 145.-. (canceled)46. A method for fixing a prosthesis comprising:a) mixing a dry powder composition comprising a calcium phosphate component and a calcium sulfate component with an aqueous liquid;b) injecting the resulting composition from step a) into a bone cavity;c) introducing a prosthesis into the bone cavity; andd) allowing the injectable composition to harden in vivo.47. The method of claim 46 , wherein the calcium phosphate component is chosen from tetracalcium phosphate (TTCP) claim 46 , monocalcium phosphate monohydrate (MCPM) claim 46 , dicalcium phosphate dihydrate (DCPD) claim 46 , anhydrous dicalcium phosphate (DCPA) claim 46 , dicalcium phosphate (OCP) claim 46 , tricalcium phosphate (TCP) claim 46 , and octocalcium phosphate (OCP).48. The method of claim 46 , wherein the calcium sulfate component is chosen from a hardened particulate calcium sulfate and a calcium sulfate hemihydrate.49. The method of claim 48 , wherein the hardened particulate calcium sulfate is calcium sulfate dihydrate.50. The method of claim 48 , wherein the calcium sulfate hemihydrate is in the α-form.51. The method of claim 46 , wherein the calcium sulfate component is present in an amount up to 60 wt % of the dry powder composition.52. The method of claim 46 , wherein the calcium sulfate component is present in an amount ranging from 10 wt % to 40 wt % of the dry powder ...

Подробнее
Номер записи: 53
17-10-2013 дата публикации

Calcium Phosphate Cements and Methods for Using the Same

Номер: US20130273118A1
Автор: Constantz Brent R., Delaney David, Yetkinler Duran N.
Принадлежит:

Methods and compositions for producing flowable compositions, e.g. pastes, that set into calcium phosphate products are provided. In the subject methods, dry reactants that include a calcium source and a phosphate source are combined with a setting fluid to produce the flowable composition. A feature of the subject methods is that the dry reactants include a particulate calcium and/or phosphate reactant having a mean particle size of less than about 8 μm and narrow size distribution. Also provided are the compositions themselves as well as kits for use in practicing the subject methods. The subject methods and compositions produced thereby find use in a variety of applications, including the repair of hard tissue defects, e.g., bone defects. 118.-. (canceled)19. A flowable composition that sets into a calcium phosphate containing product , wherein said composition is produced by a method comprising:combining:(a) a setting fluid; and(b) a dry reactant component comprising a first particulate calcium and/or phosphate reactant having a mean particle size of less than about 8 μm and narrow particle size distribution;in a ratio sufficient to produce said flowable composition.20. The composition according to claim 19 , wherein said composition is a paste.21. The composition according to claim 19 , wherein said composition is a clay.22. A method of repairing a hard tissue defect claim 19 , said method comprising:applying to the site of said defect a flowable composition that sets into a calcium phosphate containing product, wherein said composition is produced by a method comprising:combining:(a) a setting fluid; and(b) a dry reactant component comprising a first particulate calcium and/or phosphate reactant having a mean particle size of less than about 8 μm and narrow particle size distribution;in a ratio sufficient to produce said flowable composition.23. A kit comprising:a dry reactant component comprising a first particulate calcium and/or phosphate reactant having a ...

Подробнее
Номер записи: 54
24-10-2013 дата публикации

BIOLOGIC BONDING AGENT

Номер: US20130281549A1
Автор: Bonutti Peter M.
Принадлежит:

A sterile biofilm could be engineered to isolate the glue-like substance while eliminating the adverse properties of the bacteria. The resulting sterile glue-like substance would be used to help the cells stick to the support structure. The engineered biofilm could be added to the support structure in the laboratory that produces the support structure or just prior to the addition of the cells by the user. Alternatively, the biofilm and support structure could be combined intra-corporally. This biofilm also could be used as an independent polysaccharide based adhesive with mild to moderate adhesion forces. The biofilm could serve as a surgical adhesion or grouting for cells, for tissue fixation (soft tissue to soft tissue, soft tissue to bone, etc.) and as a sealant. The biofilm could be used in conjunction with other implants and devices. The biofilm could be used to coat a stent. 1. A biologic bonding agent comprising:an engineered adhesive derived at least in part from a bacterial source; andthe adhesive being configured to be collected, processed to be substantially free of viable bacteria, and placed in a container,wherein adhesive properties of the bacterial source are substantially maintained.2. The bonding agent of claim 1 , wherein the bacterial source includes biofilm.3. The bonding agent of claim 1 , wherein at least a portion of the adhesive is polysaccharide based.4. The bonding agent of claim 1 , wherein the adhesive is configured to be coated on or impregnated in at least a portion of an implant.5. The bonding agent of claim 1 , wherein at least a portion of the adhesive is biodegradable.6. The bonding agent of claim 1 , wherein the adhesive is configured to be coated on or impregnated in at least a portion of a stent.7. The bonding agent of claim 1 , wherein the adhesive is configured to be applied to at least a portion of a collagen material.8. The bonding agent of claim 1 , wherein the adhesive is configured to promote attachment of cells to a ...

Подробнее
Номер записи: 55
07-11-2013 дата публикации

IN SITU BONDS

Номер: US20130295037A1
Автор: MILBOCKER Michael T.
Принадлежит: PrometheanSurgical Devices, LLC

A biocompatible tissue-bonding adhesive composition having a polyol of functionality N. The polyol being terminated has at least one polyisocyanate in solution with at least (N−1) % of the solution having free polyisocyanate. N may be in the range 1.5-8. The polyol may be a branched polypropylene/polyethylene oxide copolymer. 139.-. (canceled)40. A method for covalent bonding of tissue , which comprises: a copolymer comprising polyether monomers and from 10% to 30% of propylene oxide monomers;', 'from 23 to 39 wt. % of at least one polyisocyanate selected from the group consisting of 2,4-touluene diisocyanate, 2,6-toluene diisoscyanate, and isophorone diisocyanate; and', 'from 1 to 5 wt. % of trimethylolpopane;', 'wherein the prepolymer is a liquid, water-soluble, and comprises from 1.5 to 5% free polyisocyanate content; and, 'providing a cyanate-terminated hydrophilic prepolymer comprisingapplying said prepolymer to tissue such that said prepolymer forms a bond with such tissue.41. The method of claim 40 , further comprising dissolving the prepolymer in water at a prepolymer to water ratio of 10:1 to 20:1.42. The method of wherein the prepolymer has a viscosity less than 20 claim 40 ,000 cps.43. The method of wherein the prepolymer has a viscosity less than 10 claim 40 ,000 cps.44. The method of wherein the prepolymer has a solid to liquid transition temperature temperature of less than 20° C.45. The method of wherein the copolymer of polyether monomers comprises PE/PO in a ratio of 80:20.46. The method of wherein the copolymer of polyether monomers is a random copolymer.47. The method of wherein the copolymer of polyether monomers is a block copolymer.48. The method of wherein the prepolymer bonds to tissue in less than 120 seconds.49. The method of wherein the copolymer has a molecular weight of from 800 to 5 claim 40 ,000. 1. Field of the InventionThis invention relates to synthetic surgical adhesives/sealants and tissue bonds created by reacting the adhesive ...

Подробнее
Номер записи: 56
07-11-2013 дата публикации

MEDICAL ADHESIVE FILM

Номер: US20130295345A1
Автор: GUAN Hongxia, PEI Fuxing, Peng Bo, SONG Jiuhong
Принадлежит:

An adhesive film including an upper surface including a developing reference axis. The adhesive film is simple in structure, accurate in positioning, and convenient for practice. 12. An adhesive film , comprising an upper surface comprising a developing reference axis ().223. The adhesive film of claim 1 , wherein the developing reference axis () is provided with reference numbers ().3. The adhesive film of claim 2 , wherein{'b': 1', '1, 'i': a,', 'b, 'the adhesive film comprises an uppermost adhesive film and a plurality of layers of inner adhesive films (. . . );'}{'b': 1', '1, 'i': a,', 'b, 'the inner adhesive films (. . . ) are disposed beneath the uppermost adhesive film;'}{'b': 2', '2', '2, 'i': a,', 'b, 'each of the inner adhesive films comprises an upper surface comprising a reference axis (. . . ) being the same as the developing reference axis () arranged on the uppermost adhesive film; and'}{'b': 2', '2, 'i': a,', 'b, 'the reference axis (. . . ) arranged on each of the inner adhesive films superposes with one another.'}4221133a,ba,ba,b. The adhesive film of claim 3 , wherein the reference axis (. . . ) arranged on each inner adhesive film (. . . ) is provided with reference numbers (. . . ).52. The adhesive film of claim 1 , wherein the developing reference axis () is in a grid structure formed by arranging transverse lines and vertical lines at equal intervalss between each other.622a,b. The adhesive film of claim 3 , wherein the reference axis (. . . ) arranged on each inner adhesive film is in a grid structure formed by arranging transverse lines and vertical lines at equal intervals between each other.722a,b. The adhesive film of claim 4 , wherein the reference axis (. . . ) arranged on each inner adhesive film is in a grid structure formed by arranging transverse lines and vertical lines at equal intervals between each other.82. The adhesive film of claim 5 , wherein vertical lines and/ or transverse lines of the developing reference axis () ...

Подробнее
Номер записи: 57
07-11-2013 дата публикации

MEDICAL ADHESIVE COMPOSITION

Номер: US20130296459A1
Автор: Choi Jae-Chul, Kim Chul Joong, Mie Iwamoto, Poo Haryoung, Sung Moon-Hee, UYAMA Hiroshi
Принадлежит:

The present invention provides a medical adhesive composition containing poly-gamma-glutamic acid or its salt; and sugar or sugar alcohol, which is edible, water-soluble, anionic and biodegradable. The invention also provides a thickener composition containing poly-gamma-glutamic acid, which can be used as a moisture-absorbing agent, a moisturizing agent and a raw material for cosmetic products.

Подробнее
Номер записи: 58
07-11-2013 дата публикации

IN SITU BONDS

Номер: US20130296460A1
Автор: MILBOCKER Michael T.
Принадлежит: Promethean Surgical Devices, LLC

A biocompatible tissue-bonding adhesive composition having a polyol of functionality N. The polyol being terminated has at least one polyisocyanate in solution with at least (N−1)% of the solution having free polyisocyanate. N may be in the range 1.5-8. The polyol may be a branched polypropylene/polyethylene oxide copolymer. 139.-. (canceled)40. A biocompatible composition comprisinga cyanate-terminated hydrophilic prepolymer comprising:a copolymer comprising polyether monomers and from 10% to 30% of propylene oxide monomers;from 23 to 39 wt. % of at least one polyisocyanate selected from the group consisting of 2,4-touluene diisocyanate, 2,6-toluene diisoscyanate, and isophorone diisocyanate; andfrom 1 to 5 wt. % of trimethylolpopane;wherein the prepolymer is a liquid, water-soluble, and comprises from 1.5 to 5% free polyisocyanate content.41. The biocompatible composition of wherein the prepolymer is dissolvable in water at a prepolymer to water ratio of 10:1 to 20:1.42. The biocompatible composition of wherein the prepolymer has a viscosity less than 20 claim 40 ,000 cps.43. The biocompatible composition of wherein the prepolymer has a viscosity less than 10 claim 40 ,000 cps.44. The biocompatible composition of wherein the prepolymer has a solid to liquid transition temperature of less than 20° C.45. The biocompatible composition of wherein the copolymer of polyether monomers comprises PE/PO in a ratio of 80:20.46. The biocompatible composition of wherein the copolymer of polyether monomers is a random copolymer.47. The biocompatible composition of wherein the copolymer of polyether monomers is a block copolymer.48. The biocompatible composition of wherein the copolymer has a molecular weight of from 800 to 5 claim 40 ,00049. A hydrated claim 40 , biocompatible composition comprising:at least one isocyanate terminated hydrophilic prepolymer derived from reaction of an organic polyisocyanate, at least one oxyethylene-based copolymer, and a triol; andan aqueous ...

Подробнее
Номер записи: 59
21-11-2013 дата публикации

COMPOSITION CONTAINING INJECTABLE SELF-HARDENED APATITE CEMENT

Номер: US20130309214A1
Автор: Fazan Fazilah Binti, Ibrahim Shirin Binti, Kader Bashah Nor Shahida Binti, Sabudin Salina, Sahid Sudirman Bin, Wan Sulaiman Wan Ruzaini Bin
Принадлежит: SIRIM Berhad

A method of producing an injectable calcium phosphate paste by a process in which calcium phosphate precursors are mixed with the setting fluids to form a self-hardened apatite cement is disclosed. The produced apatite cement is biocompatible, bioactive and biodegradable in the body. The pH value of said apatite cement is approximately 7 with compressive strength between 10-30 MPa and the setting process will not generate.temperature >37° C. The self-hardened apatite (SHA) cement is found to be bioresorbable and can be used for bone fillers, fixation of broken bones or artificial joints in human and also appropriate for use as a delivery vehicle. 1. A composition of injectable self-hardened apatite cement comprising:{'sub': 3', '4', '2', '4', '4', '2, 'a. a main matrix comprising tri-calcium phosphate (TCP; Ca(PO)) and tetra-calcium phosphate (TTCP; Ca(PO)O),'}{'sub': 2', '3', '6', '8', '7', '6', '5', '3', '7', '2, 'b. hardening agents comprising sodium carbonate (NaCO), citric acid, (CHO) and sodium citrate (CHNaO.2HO),'}c. setting fluids andd. filler and pH stabiliser.2. The composition according to wherein the filler and pH stabiliser is hydroxyapatite (Ca(PO)(OH)).3. The composition according to claim 1 , wherein the weight ratio of tri-calcium phosphate to tetra-calcium phosphate is in the range of 45:55 to 55:45.4. The composition according to claim 1 , wherein said sodium carbonate is present in an amount ranging from about 5 to 10 weight percentage.5. The composition according to claim 1 , wherein said citric acid is present in an amount ranging from about 20 to 30 weight percentage.6. The composition according to claim 1 , wherein said sodium citrate is present in an amount ranging from about 5 to 10 weight percentage.7. The composition according to claim 1 , wherein said filler and/or pH stabiliser is present in an amount ranging from about 1 to 5 weight percentage.8. The composition according to claim 1 , wherein the setting fluids are selected from a ...

Подробнее
Номер записи: 60
21-11-2013 дата публикации

PASTE-LIKE BONE CEMENT

Номер: US20130310466A1
Автор: VOGT Sebastian
Принадлежит:

Kit for producing a bone cement paste, comprising a paste A and a paste B; paste A comprising at least one monomer for radical polymerization, at least one peroxide polymerization initiator and at least one tertiary amine, at least one amidine or a mixture of a tertiary amine and amidine; paste B comprising at least one monomer for radical polymerization, at least one heavy metal compound as polymerization accelerator, and as polymerization co-accelerator at least one sulfimide, at least one dicarboxylic acid imide or a mixture thereof, at least one of the pastes A and B comprising at least one filling agent that is insoluble in the monomer of paste A and/or the monomer of paste B. 1. Kit comprising a paste A and a paste B ,wherein (a1) at least one monomer for radical polymerisation with a boiling point below 120° C. at a pressure of 1,013 mbar;', '(a2) at least one peroxide as polymerisation initiator; and', '(a3) as polymerisation co-accelerator, at least one tertiary amine, at least one amidine or a mixture of at least one tertiary amine and at least one amidine; and, '(a) paste A contains'} (b1) at least one monomer for radical polymerisation with a boiling point below 120° C. at a pressure of 1,013 mbar;', '(b2) at least one heavy metal compound as polymerisation accelerator; and', '(b3) as polymerisation co-accelerator, at least one sulfimide, at least one dicarboxylic acid imide or a mixture of at least one sulfimide and at least one dicarboxylic acid imide;, '(b) paste B contains'}wherein at least one of the pastes A and B contains, as component (a4) and/or (b4), at least one filling agent that is insoluble in (a1) and/or (b1), respectively.2. Kit according to claim 1 , wherein the at least one monomer (a1) and/or (b1) for radical polymerisation is a methacrylate monomer.3. Kit according to claim 1 , wherein paste A and paste B contain an amount of the at least one monomer (a1) and/or (b1) for radical polymerisation in a range of 15 to 85% by weight claim 1 ...

Подробнее
Номер записи: 61
28-11-2013 дата публикации

TISSUE ADHESIVE BASED ON TRIFUNCTIONAL ASPARTATES

Номер: US20130317134A1
Автор: Eggert Christoph, Heckroth Heike
Принадлежит: Bayer Intellectual Property GmbH Creative Campus Monheim

The present invention relates to a compound of formula (I) wherein R, Reach independently of the other are identical or different organic radicals which do not contain Zerewitinoff-active hydrogen, and R, R, Reach independently of the others are saturated, linear or branched organic radicals which do not contain Zerewitinoff-active hydrogen and which are also optionally substituted in the chain by heteroatoms, for use in a polyurea system which is provided in particular for sealing, bonding, gluing or covering cell tissue. The invention further provides a polyurea system comprising the compound according to the invention, and a metering system for the polyurea system according to the invention. 116-. (canceled)18. The compound according to claim 17 , wherein the radicals R claim 17 , Rand Reach independently of the others are linear or branched claim 17 , saturated claim 17 , aliphatic C1 to C12 hydrocarbon radicals.19. The compound according to claim 17 , wherein the radicals R claim 17 , Rand Reach independently of the others are saturated claim 17 , aliphatic C3 to C6 hydrocarbon radicals.20. The compound according to claim 17 , wherein the radicals Rand Reach independently of the other are linear or branched organic C1 to C10.21. The compound according to claim 17 , wherein the radicals Rand Reach independently of the other are linear or branched C2 to C4 aliphatic hydrocarbon radicals.22. The compound according to claim 17 , wherein the radicals Rand Rare each identical and/or the radicals R claim 17 , R claim 17 , Rare each identical.23. A polyurea system comprising aliphatic polyisocyanates A1) with', 'polyols A2),, 'as component A) isocyanate-functional prepolymers obtainable by reaction of'}{'claim-ref': {'@idref': 'CLM-00017', 'claim 17'}, 'as component B) the amino-functional compound according to ,'}optionally as component C) organic fillers, which in particular can have a viscosity at 23° C., measured in accordance with DIN 53019, in the range of from ...

Подробнее
Номер записи: 62
05-12-2013 дата публикации

Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers

Номер: US20130325061A1
Автор: Ingenito Edward P., Krom James A., Schwarz Alexander, Tsai Larry W.
Принадлежит: Aeris Therapeutics, LLC

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema. 149-. (canceled)50. A method of attaching a first tissue to a second tissue of a patient in need thereof , comprising the step of applying to said first tissue or said second tissue or both an effective amount of a hydrogel , wherein said hydrogel is prepared from(a) a first non-natural polymer and a first cross-linker; said first non-natural polymer comprises a plurality of pendant first nucleophilic groups; and said first cross-linker comprises at least two pendant first electrophilic groups; or(b) a second non-natural polymer and a second cross-linker; said second non-natural polymer comprises a plurality of second electrophilic groups; and said second cross-linker comprises at least two pendant second nucleophilic groups,thereby attaching said first tissue to said second tissue.5155-. (canceled)56. The method of claim 50 , wherein said hydrogel is prepared from a first non-natural polymer and a first cross-linker; and said first nucleophilic groups are selected from the group consisting of alcohols claim 50 , amines ...

Подробнее
Номер записи: 63
05-12-2013 дата публикации

TISSUE ADHESIVE BASED ON NITROGEN-MODIFIED ASPARTATES

Номер: US20130325062A1
Автор: Eggert Christoph, Heckroth Heike
Принадлежит: Bayer Intellectual Property GmbH

The invention relates to a polyurea system comprising as component A) isocyanate-functional prepolymers which can be obtained by reacting aliphatic isocyanates A1) with polyols A2) that can have a number-average molecular weight of =400 g/mol and an average OH functionality of 2 to 6 in particular; and as component B) amino-functional aspartic acid esters of the general formula (I) in which X is an organic group containing a secondary amino function, R1, R2 are the same or different organic groups that do not have Zerewitinoff-active hydrogen, and n is a whole number of at least 2, in particular for sealing, bonding, gluing, or covering cell tissue. The invention also relates to a metering system for the polyurea system according to the invention. 115-. (canceled)18. The polyurea system as claimed in claim 17 , wherein Rand Rin each case independently of one another or simultaneously are a linear or branched saturated organic radical optionally also substituted in the chain with heteroatoms.19. The polyurea system as claimed in claim 16 , wherein the radicals Rand Rin each case independently of one another are linear or branched C1 to C10 organic radicals.20. The polyurea system as claimed in claim 17 , wherein Rand Rin each case independently of one another or simultaneously are a linear or branched claim 17 , saturated claim 17 , aliphatic C2 to C6 claim 17 , and the radicals Rand Rin each case independently of one another are linear or branched C2 to C4 aliphatic hydrocarbon radicals.21. The polyurea system as claimed in claim 16 , wherein the polyols A2) contain polyesterpolyols and/or polyester-polyether-polyols and/or polyetherpolyols with an ethylene oxide fraction between 60 and 90% by weight.22. The polyurea system as claimed in claim 16 , wherein the polyols A2) contain polyester-polyether-polyols and/or polyetherpolyols with an ethylene oxide fraction between 60 and 90% by weight.23. The polyurea system as claimed in claim 16 , wherein the polyols A2) ...

Подробнее
Номер записи: 64
12-12-2013 дата публикации

Means for Controlled Sealing of Endovascular Devices

Номер: US20130331929A1
Автор: Ashish Sudhir Mitra, Ben Colin Bobillier, Pak Man Victor Wong
Принадлежит: Endoluminal Sciences Pty Ltd

Expandable sealing means for endoluminal devices have been developed for controlled activation. The devices have the benefits of a low profile mechanism (for both self-expanding and balloon-expanding prostheses), contained, not open, release of the material, active conformation to the “leak sites” such that leakage areas are filled without disrupting the physical and functional integrity of the prosthesis, and on-demand, controlled activation, that may not be pressure activated.

Подробнее
Номер записи: 65
19-12-2013 дата публикации

ADHESIVE COMPOSITION FOR SOFT TISSUES, ADHESIVE COMPOSITION FOR WOUND DRESSING OR WOUND DRESSING COMPOSITION

Номер: US20130336882A1
Автор: Aoki Shinya, Arata Masami, ASADA Noriaki, Miyakoshi Shoichi, Naruse Hiroshi
Принадлежит: Mitsui Chemicals, Inc.

The adhesive composition for soft tissues, the adhesive composition for wound dressing or the wound dressing agent composition of the present invention is an adhesive composition for soft tissues, an adhesive composition for wound dressing or a wound dressing agent composition, comprising a monomer (A), a polymer (B) and a polymerization initiator composition (C) containing an organoboron compound, and is characterized by having a viscosity of 0.4 to 75,000 cp within 30 seconds after mixing of the components (A), (B) and (C). The composition of the present invention not only has low toxicity, low harmfulness and high adhesive strength but also is excellent in workability during application and is capable of forming films of excellent properties. 2. The adhesive composition for soft tissues claim 1 , the adhesive composition for wound dressing or the wound dressing composition as claimed in claim 1 , wherein a film claim 1 , which is obtained from said adhesive composition or wound dressing composition claim 1 , is given 24 hours after the preparation of the composition and has a thickness of not less than 0.1 μm claim 1 , a length of not less than 25 mm and a width of not less than 2 mm claim 1 , has a flexural elastic modulus claim 1 , as measured under the conditions of a test rate of 2 mm/min claim 1 , of not more than 750 MPa and a tensile elongation claim 1 , as measured under the conditions of a test rate of 1 mm/min claim 1 , of not less than 5%.3. The adhesive composition for soft tissues claim 1 , the adhesive composition for wound dressing or the wound dressing composition as claimed in claim 1 , which further comprises a polymerization inhibitor (D).4. The adhesive composition for soft tissues claim 3 , the adhesive composition for wound dressing or the wound dressing composition as claimed in claim 3 , wherein the content of the polymerization inhibitor (D) is in the range of 10 to 5000 ppm based on the monomer (A) claim 3 , the content of the monomer (A ...

Подробнее
Номер записи: 66
26-12-2013 дата публикации

Cross-linked polymers and implants derived from electrophilically activated polyoxazoline

Номер: US20130345334A1
Автор: Jan Cornelis Maria Van Hest, Johannes Caspar Mathias Elizabeth Bender, Richard Hoogenboom
Принадлежит: Bender Analytical Holding BV

One aspect of the invention relates to a biocompatible, covalently cross-linked, polymer that is obtained by reacting an electrophilically activated polyoxazoline (EL-POX) with a nucleophilic cross-linking agent, said electrophilically activated POX comprising m electrophilic groups; and said nucleophilic cross-linking agent comprising n nucleophilic groups, wherein the m electrophilic groups are capable of reaction with the n nucleophilic groups to form covalent bonds; wherein m≧2, n≧2 and m+n≧5; wherein at least one of the m electrophilic groups is a pendant electrophilic group and/or wherein m≧3; and wherein the EL-POX comprises an excess amount of electrophilic groups relative to the amount of nucleophilic groups contained in the nucleophilic cross-linking agent. The invention further relates to biocompatible medical products comprising such a cross-linked POX-polymer. Also provided is a kit for producing a biocompatible, cross-linked POX-polymer. The invention further provides a tissue adhesive medical product comprising at least 1% by weight of dry matter of EL-POX, said EL-POX comprising at least 2 electrophilic groups, including at least one pendant electrophilic group. The polymers according to the invention have excellent implant and/or sealing characteristics.

Подробнее
Номер записи: 67
02-01-2014 дата публикации

BONE SUBSTITUTE COMPOSITIONS, METHODS OF PREPARATION AND CLINICAL APPLICATIONS

Номер: US20140004161A1
Автор: KUMTA PRASHANT NAGESH, ROY ABHIJIT, SFEIR Charles S.
Принадлежит: University of Pittsburgh - of the Commonwealth System of Higher Education

The present invention relates to bone substitute compositions and methods of their preparation, and their use in a wide variety of clinical applications. The compositions include calcium phosphate, acidic calcium salt, basic calcium salt, sodium hydrogen phosphate and porogen. The compositions further include a mixing liquid. The compositions can optionally include biological signaling molecules and/or a growth compound. Further, the compositions can optionally include a plasticizer. 141-. (canceled)42. A method of repairing or replacing defective native bone tissue , comprising: combining calcium phosphate, acidic calcium salt, basic calcium salt, material selected from the group consisting of monosodium hydrogen phosphate, disodium hydrogen phosphate and mixtures thereof, and porogen to form a powder component; and', 'mixing the powder component with a liquid colloidal mixture comprising nanoparticulate calcium phosphate and calcium salt;, 'preparing a bone substitute composition, comprisingobtaining a patient having defective native bone tissue; andadministering in vivo the bone substitute composition in a form selected from the group consisting of paste, putty and cement, into the patient at the site of the defective native bone tissue.43. The method of claim 42 , wherein the repairing or replacing defective native bone tissue is carried out in the absence of a biological growth component.44. The method of claim 42 , wherein the native bone tissue is in an area selected from the group consisting of orthopedic claim 42 , dental and craniofacial.45. The method of claim 42 , wherein the administering of the bone substitute composition is selected from the group consisting of injecting and implanting the bone substitute composition into the patient.46. The method of claim 42 , wherein surface area of the bone substitute composition is greater than surface area of the powder component.47. A method for delivering cellular and biological material to a target site in a ...

Подробнее
Номер записи: 68
16-01-2014 дата публикации

BIODEGRADABLE PARTICLE, VASCULAR EMBOLIZATION MATERIAL AND METHOD FOR PRODUCING BIODEGRADABLE PARTICLES

Номер: US20140018505A1
Автор: Fujita Masaki, Nakanishi Megumi, Takahashi Yoshitake, Tanahashi Kazuhiro, Yamamura Yasufumi
Принадлежит: Toray Industries, Inc.

A biodegradable particle including a block copolymer produced by copolymerization of a biodegradable copolymer having a structure composed of hydroxycarboxylic acid a1, whose homopolymer produced by homopolymerization has a glass transition point of not less than 40° C. and hydroxycarboxylic acid a2, whose homopolymer produced by homopolymerization has a glass transition point of not more than −40° C.; a water-soluble polymer comprising a functional group selected from the group consisting of a hydroxyl group, amino group and carboxylic acid group at each of both ends; and a polyvalent compound comprising 2 or more functional groups each selected from the group consisting of a hydroxyl group, amino group and carboxylic acid group; wherein a ratio of mass of said structure composed of hydroxycarboxylic acid a2 to mass of said biodegradable copolymer is 30 to 90% by mass. 1. A biodegradable particle comprising a block copolymer produced by copolymerization of:a biodegradable copolymer having a structure composed of hydroxycarboxylic acid a1, whose homopolymer produced by homopolymerization has a glass transition point of not less than 40° C., and hydroxycarboxylic acid a2, whose homopolymer produced by homopolymerization has a glass transition point of not more than −40° C.;a water-soluble polymer comprising a functional group selected from the group consisting of a hydroxyl group, amino group and carboxylic acid group at each of both ends; anda polyvalent compound comprising 2 or more functional groups each selected from the group consisting of a hydroxyl group, amino group and carboxylic acid group;wherein thea ratio of the mass of said structure composed of hydroxycarboxylic acid a2 to the mass of said biodegradable copolymer is 30 to 90% by mass.3. The biodegradable particle according to claim 1 , wherein a 40% compression load in a water-saturated state is not more than 500 mN and claim 1 , when a compression rate in the water-saturated state is 10% claim 1 , ...

Подробнее
Номер записи: 69
16-01-2014 дата публикации

MEDICAL ADHESIVE

Номер: US20140018510A1
Автор: Kawakami Naoaki, MAEDA HIROAKI
Принадлежит:

The present invention is directed to providing a safe medical adhesive, a cured body of which is hard to be degraded and decomposed and thus stable and the cured body generates less amount of acid, aldehyde, etc. due to degradation/decomposition. The medical adhesive includes a hydrophilic urethane prepolymer (UP) obtained by reacting a polyisocyanate component (A) containing a fluorine-containing non-aromatic polyisocyanate compound (A1) as an essential ingredient and a polyol component (B) containing a hydrophilic polyol (B1) as an essential ingredient, wherein a chlorine content in a chlorine-containing organic compound based on the weight of the hydrophilic urethane prepolymer (UP) is 0.005 wt % or less. 2. The medical adhesive according to claim 1 , wherein a isocyanate group content in the hydrophilic urethane prepolymer (UP) based on the weight of the hydrophilic urethane prepolymer (UP) is 1 to 10 wt %.3. The medical adhesive according to claim 1 , wherein the polyol component (B) is a polyol comprising a polyether polyol.4. The medical adhesive according to claim 1 , wherein the hydrophilic polyol (B1) is a polyether polyol having an oxyethylene group content of 30 to 100 wt %.5. The medical adhesive according to claim 1 , wherein the polyol component (B) is a mixture of a random co-adduct of ethylene oxide and propylene oxide to a diol and a polypropylene glycol.6. The medical adhesive according to claim 1 , for use in bonding a body tissue.7. The medical adhesive according to claim 6 , wherein the body tissue is at least one tissue selected from the group consisting of blood vessel claim 6 , heart claim 6 , respiratory organ and digestive organ. The present invention relates to a medical adhesive.As a medical adhesive for bonding body tissues such as blood vessel, heart, respiratory organ and digestive organ, using e.g., a hydrophilic urethane prepolymer having isocyanate group in terminal(s) of itself, which is obtained by the reaction between a fluorine ...

Подробнее
Номер записи: 70
30-01-2014 дата публикации

MONO-LAYER THIN FILM ADHESIVE COMPOUNDS AND METHODS OF SYNTHESIS AND USE

Номер: US20140030944A1
Автор: Broussard Joel L., Dalsin Jeffrey L., Koepsel Justin T., Lyman Arinne N., Murphy John L., Vollenweider Laura L., Winterbottom Neil
Принадлежит: KNC NER ACQUISITION SUB, INC.

The invention relates provides synthetic medical adhesives which exploit plant derivatives to form covalent bonds with amines and thiols on tissue surfaces. 2. The compound of claim 1 , wherein Lis a residue of a C1-C15 alkyl lactone or lactam claim 1 , a poly C1-C15 alkyl lactone or lactam claim 1 , a polyester claim 1 , or a compound comprising the formula Y—R—C(═O)—Y claim 1 , wherein Yis OH claim 1 , NHR claim 1 , a halide claim 1 , or an activated derivative of OH or NHR;{'sub': '17', 'Ris a branched or unbranched C1-C15 alkyl group; and'}{'sub': '6', 'Yis NHR, a halide, or OR.'}3. The compound of claim 2 , wherein said alkykl lactone is a polycaprolactone.4. The compound of claim 1 , wherein Lis a residue of an alkylene diol claim 1 , an alkylene diamine or a poly(alkylene oxide) polyether or derivative thereof.5. The compound of claim 4 , wherein Lis a poly(alkylene oxide) or —O—CHCH—O—CHCH—O—.6. The compound of claim 1 , wherein Lor Lis a residue of a C1-C15 alkyl lactone or lactam claim 1 , a poly C1-C15 alkyl lactone or lactam claim 1 , or a compound comprising the formula Y—R—C(═O)—Y claim 1 , wherein Yis OH claim 1 , NHR claim 1 , a halide claim 1 , or an activated derivative of OH or NHR;{'sub': '17', 'Ris a branched or unbranched C1-C15 alkyl group; and'}{'sub': '6', 'Yis NHR, a halide, or OR.'}7. The compound of claim 6 , wherein said alky lactone is polycaprolactone.8. The compound of claim 1 , wherein X claim 1 , X claim 1 , Xand Xare each O or NH.9. The compound of claim 1 , wherein R claim 1 , R claim 1 , Rand Rare each —CHCH—.10. The compound of claim 1 , wherein X claim 1 , X claim 1 , Xand Xare each O.11. The compound of claim 1 , wherein R claim 1 , R claim 1 , Rand Rare each —CH—.12. The compound of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , Rand Rare a branched or unbranched alkane.13. The compound of claim 12 , wherein R claim 12 , R claim 12 , R claim 12 , R claim 12 , Rand Rare —CH—CH— or CH—CH—CH—.14. The compound ...

Подробнее
Номер записи: 71
30-01-2014 дата публикации

PASTE-LIKE BONE CEMENT

Номер: US20140031451A1
Автор: VOGT Sebastian
Принадлежит: HERAEUS MEDICAL GMBH

A paste contains at least one monomer for radical polymerisation, at least one polymer that is soluble in said at least one monomer for radical polymerisation, and at least one filling agent that is poorly soluble or insoluble in said at least one monomer for radical polymerisation. The filling agent is a particulate inorganic calcium salt comprising the following properties: at least 90% by weight of the particulate inorganic calcium salt have a particle size of less than 63 μm, as determined by means of sieve analysis; and the solubility in water of the particulate inorganic calcium salt at 20° C. is less than 8.5 g per litre. A kit and the paste is usable for mechanical fixation of articular endoprostheses, for covering skull defects, for filling bone cavities, for femuroplasty, for vertebroplasty, for kyphoplasty, for the manufacture of spacers or for the production of carrier materials for local antibiotics therapy, as well as a form body. 1. Paste containing at least one monomer for radical polymerisation , at least one polymer that is soluble in said at least one monomer for radical polymerisation , and at least one filling agent that is poorly soluble or insoluble in said at least one monomer for radical polymerisation , wherein the at least one filling agent is a particulate inorganic calcium salt comprising the following properties i) and ii):i) at least 90% by weight of the particulate inorganic calcium salt have a particle size of less than 63 μm, as determined by means of sieve analysis;ii) the solubility in water of the particulate inorganic calcium salt at 20° C. is less than 8.5 g per litre.2. Paste according to claim 1 , wherein the filling agent comprises the properties i) and ii):i) at least 90% by weight of the particulate inorganic calcium salt have a particle size of less than 20 μm, as determined by means of sieve analysis;ii) the solubility in water of the particulate inorganic calcium salt at 20° C. is less than 5 g per litre.3. Paste ...

Подробнее
Номер записи: 72
06-02-2014 дата публикации

Method and Device for Coating of a Medical Implant

Номер: US20140033970A1
Автор: BÜCHNER Hubert, VOGT Sebastian
Принадлежит: HERAEUS MEDICAL GMBH

The invention relates to a method for coating of a medical implant that can be used to apply a calcium salt to the surface of a medical implant easily and without expensive coating equipment and little expenditure of time. 115.-. (canceled)16. Device for coating a medical implant comprising a hollow body and a body that is arranged in the hollow body such as to be mobile therein and can be moved out of the hollow body at least in part , and comprises a calcium salt with a Mohs hardness of no more than 5.5 on at least one of its surfaces , and a pharmaceutical agent , wherein the porosity of the body is in the range from 10-70% by volume.17. The device according to claim 16 , wherein the device is used in a method for coating of a medical implant claim 16 , said method comprising providing a medical implant that includes at least one surface to be coated; and rubbing said body having the calcium salt-containing surface over the at least one medical implant surface to be coated such that said surface of the medical implant is coated with the at least one calcium salt.18. The device according to wherein the medical implant is an articular endoprosthesis.19. The device according to wherein the medical implant surface to be coated has a mean roughness Rof at least 0.5 μm.20. The device according to wherein the medical implant consists essentially of titanium or a titanium alloy.21. The device according to wherein the water fraction of the body is in the range from 20-70% by weight.22. The device according to wherein the solubility of the at least one calcium salt in water at a temperature of 25° C. is at least 2 g/l.23. The device according to wherein the body contains 50-100% by weight calcium salts.24. The device according to wherein the calcium salt is selected from the group consisting of calcium sulfates claim 16 , calcium phosphates claim 16 , calcium hydrogenphosphates claim 16 , and calcium carbonate.25. The device according to wherein the calcium sulfate is ...

Подробнее
Номер записи: 73
13-02-2014 дата публикации

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same

Номер: US20140041547A1
Автор: Ian J. Handley, Joanna Wang, Neil Winterbottom, Ronald Dieck
Принадлежит: Tenaxis Medical Inc

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.

Подробнее
Номер записи: 74
13-02-2014 дата публикации

BIOCOMPATIBLE ADHESIVE POLYMERS

Номер: US20140041802A1
Автор: GU Yansong, Karp Floyd Brian, Klein Josef Peter, Sahm Roger A.
Принадлежит:

Block co-polymers including a hydrophilic block and a hydrophobic poly(amino acid) block which further includes dihydroxyphenyl moieties are provided, as well as methods of making and using the same. Such block copolymers may be used to prepare biocompatible adhesives which display good adhesives properties in aqueous environments, including in in vivo applications. 2. The block co-polymer of claim 1 , wherein Y is —O—.3. The block co-polymer of claim 1 , wherein L is —O—CHCH— or —N(R′)CHCH—.4. The block co-polymer of claim 1 , wherein R is H claim 1 , methyl claim 1 , or ethyl.5. The block co-polymer of claim 1 , wherein m is 1 to about 1000.6. The block co-polymer of claim 1 , wherein p is 1 to about 5000.7. The block co-polymer of claim 1 , wherein Q is a mono- or divalent radical of a glutamic acid side chain or an aspartic acid side chain.8. The block co-polymer of claim 1 , wherein —X—Z is null.9. The block co-polymer of claim 1 , wherein —X—Z is —N(H)alkyl or —Oalkyl.10. The block co-polymer of claim 1 , wherein —X—Z is a dihydroxyphenethylamine group.11. The block co-polymer of claim 10 , wherein the dihydroxyphenethylamine group is dihydroxyphenethylamine claim 10 , L-DOPA claim 10 , norepinephrine claim 10 , or epinephrine.13. The block co-polymer of claim 1 , wherein about 10% to about 100% of the Z groups are the group of Formula II.14. A block co-polymer comprising:a first block of poly(ethylene glycol) having a number average molecular weight of about 1,000 to about 10,000; anda second block of a poly(amino acid) homopolymer having a number average molecular weight of about 500 to about 100,000,wherein the poly(amino acid) homopolymer comprises dihydroxyphenyl groups linked to one or more of the amino acid side chain groups.15. The block copolymer of claim 14 , wherein the amino acid side chain groups are selected from the group consisting imidazoles claim 14 , amines claim 14 , hydroxyls claim 14 , and carboxylates claim 14 , guanidines claim 14 , and ...

Подробнее
Номер записи: 75
20-02-2014 дата публикации

Injection Of Fibrin Sealant Including An Anesthetic In Spinal Applications

Номер: US20140052070A1
Автор: Burkinshaw Brian D., Pauza Kevin, Richards Mark I., Rogan James B., Whitlock Steven I.
Принадлежит: SPINAL RESTORATION, INC.

A method of treating a disc that is leaking nucleus pulposus through at least one defect in the annulus fibrosus. The method includes injecting a fibrin sealant into the disc to reduce at least a portion of the at least one defect, wherein the fibrin sealant injected into the disc comprises an anesthetic, fibrinogen and an activating compound, wherein at least a portion of the fibrin forms after injection, with the proviso that a corticosteroid is absent from the fibrin sealant injected into the disc. 1. A kit , comprising: a fibrinogen , thrombin , a spinal needle , and an introducer needle , wherein spinal needle is of a length that does not extend past the tip of an introducer needle during use , wherein the kit excludes corticosteroid and wherein the kit excludes a device to provide thermal energy to a disc.2. The kit of claim 1 , further comprising: one of lidocaine claim 1 , sarapin or bupivicaine.3. The kit of claim 1 , further comprising calcium chloride.4. The kit of claim 1 , further comprising an additive claim 1 , wherein the additive is selected from the group consisting of antibiotics; antiproliferative claim 1 , cytotoxic claim 1 , and antitumor drugs; analgesic; antiangiogen; antivirals; cytokines; colony stimulating factors; proteins; chemoattractants; EDTA; histamine; antihistamine; erythropoietin; antifungals; antiparasitic agents; non-corticosteroid anti-inflammatory agents; anticoagulants; oncology agents; cardiovascular drugs; glycoproteins; fibronectin; interferons; cartilage inducing factors; protease inhibitors; vasoconstrictors claim 1 , vasodilators claim 1 , demineralized bone or bone morphogenetic proteins; hormones; lipids; carbohydrates; proteoglycans; antiangiogenins; antigens; DBM; hyaluronic acid and salts thereof; polysaccharides; cellulose compounds; antibodies; gene therapy reagents; genetically altered cells claim 1 , stem cells and/or other cells; cell growth factors; type II collagen; collagen hydrolyzate; elastin; sulfated ...

Подробнее
Номер записи: 76
27-02-2014 дата публикации

RESTORATIVE MATERIALS

Номер: US20140053758A1
Автор: Booth Samantha, Nicholson John
Принадлежит: University of Greenwich

The present invention relates to restorative materials, in particular to glass-ionomer cements. More particularly, the present invention relates to glass-ionomer cements having particular utility in the repair of human hard tissue, in particular as dental restorative materials and in orthopaedic surgery. We describe a composition comprising a mixture of a glass ionomer cement and zinc phosphate. Preferably, the composition comprise from 40 to 95% by weight of glass ionomer cement and from to 60% by weight of zinc phosphate. The present invention also provides a powdered composition comprising a fluorosilicate glass and deactivated zinc oxide. Such that the zinc phosphate is formed in sith by reaction between the zinc oxide and phosphoric acid. 1. A composition comprising a mixture of a glass ionomer cement and zinc phosphate , wherein the zinc phosphate is prepared , in use , by reaction of zinc oxide and phosphoric acid; and wherein the glass ionomer cement is formed in use.2. A composition as claimed in comprising from 40 to 95% by weight of glass ionomer cement and from 5 to 60% by weight of zinc phosphate.3. A composition as claimed in comprising from 60 to 80% by weight of glass ionomer cement and from 20 to 40% by weight of zinc phosphate.4. A composition as claimed in comprising from 70 to 80% by weight of glass ionomer cement and from 20 to 30% by weight of zinc phosphate.5. A composition as claimed in comprising about 75% by weight of glass ionomer cement and about 25% by weight of zinc phosphate.6. A composition as claimed in claim wherein the glass ionomer cement is formed in situ by reaction of a precursor glass and a polyalkenoic acid.7. A composition obtainable by reacting together a glass ionomer cement precursor claim 1 , a polyalkeonoic acid claim 1 , zinc oxide and phosphoric acid.8. A precursor composition for the composition for claim 1 , the precursor composition comprising a mixture of fluorosilicate glass and deactivated zinc oxide.9. A ...

Подробнее
Номер записи: 77
27-02-2014 дата публикации

METHODS FOR SEALING WOUNDS WITH A STERILIZED COMPOSITION OF A CYANOACRYLATE MONOMER AND A POLOXAMER

Номер: US20140056839A1
Автор: Ruiz, SR. Rafael, Zhang Sheng
Принадлежит: Adhezion Biomedical, LLC

The present invention relates to compositions of cyanoacrylate monomer, a method of improving the viscosity and the curing speed with a single additive and a process of providing sterilized cyanoacrylate adhesive compositions for application in the medical field. 1. A method for sealing a wound , comprising applying a radiation-sterilized cyanoacrylate adhesive composition over a wound and allowing the composition to cure over the wound , thereby sealing the wound , wherein the radiation-sterilized cyanoacrylate adhesive composition comprises a cyanoacrylate monomer stabilized with about 2000 to about 15 ,000 parts per million of the cyanoacrylate monomer of butylated hydroxyl anisole and about 10 to about 200 parts per million of the cyanoacrylate monomer of sulfur dioxide , homogenously mixed together with about 0.04% to about 0.5% by weight of the composition of a poloxamer , and wherein the radiation-sterilized cyanoacrylate adhesive composition has a viscosity between about 20 centipoise to about 2000 centipoise.2. The method of claim 1 , wherein the viscosity of the composition is between about 20 and about 1000 centipoise.3. The method of claim 1 , wherein the viscosity of the composition is between about 20 and about 200 centipoise.4. The method of claim 1 , wherein the viscosity of the composition is between about 500 and about 2000 centipoise.5. The method of claim 1 , wherein the viscosity of the composition is between about 1000 and about 2000 centipoise.6. The method of claim 1 , wherein the poloxamer is selected from the group consisting of poloxamer 238 claim 1 , poloxamer 188 claim 1 , poloxamer 108 claim 1 , poloxamer 338 claim 1 , poloxamer 407 claim 1 , and mixtures thereof.7. The method of claim 1 , wherein the poloxamer is poloxamer 407 in an amount of about 0.04 to about 0.22% by weight of the composition.8. The method of claim 1 , wherein the poloxamer is poloxamer 238 in an amount of 0.16% to 0.45% by weight of the composition.9. The method ...

Подробнее
Номер записи: 78
06-03-2014 дата публикации

MEDICAL ADHESIVE FOR STEMMING BLEEDING

Номер: US20140065091A1
Автор: Eggert Christoph, Heckroth Heike
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to a polyurea system comprising as component A) isocyanate-functional prepolymers obtainable by reaction of aliphatic isocyanates A1) with polyols A2), which in particular can have a number-average molecular weight of ≧400 g/mol and a mean OH functionality of from 2 to 6, as component B) an amino-functional compound of the general formula (I) in which X is an organic radical containing a secondary amino function, Y is an organic radical that contains a tertiary amino group and does not contain Zerewitinoff-active hydrogen, Ris a CH—COORradical in which Ris an organic radical that does not contain Zerewitinoff-active hydrogen, a linear or branched C1- to C4-alkyl radical, a cyclopentyl radical, a cyclohexyl radical or H, Ris an organic radical that does not contain Zerewitinoff-active hydrogen, a is 1 or 2, b is 1 or 2, and a+b=2 or 3, for stemming the escape of blood, and to a metering system for the polyurea system according to the invention. 115-. (canceled)18. The polyurea system according to claim 17 , wherein R claim 17 , Reach independently of one another or simultaneously are a linear or branched claim 17 , saturated organic radical optionally substituted in the chain by hetero atoms claim 17 , in particular a linear or branched claim 17 , saturated claim 17 , aliphatic C1 to C10 claim 17 , preferably C2 to C8 claim 17 , particularly preferably C2 to C6 hydrocarbon radical and most particularly preferably a methylene claim 17 , ethylene claim 17 , propylene or butylene-radical.20. The polyurea system according to claim 19 , wherein R claim 19 , Reach independently of one another or simultaneously are a methyl claim 19 , ethyl or propyl radical.21. The polyurea system according to claim 16 , wherein R claim 16 , Rand optionally Reach independently of one another or simultaneously are a linear or branched C1 to C10 claim 16 , preferably C1 to C8 claim 16 , particularly preferably C2 to C6 claim 16 , most particularly preferably C2 ...

Подробнее
Номер записи: 79
06-03-2014 дата публикации

TISSUE ADHESIVE WITH ACCELERATED CURING

Номер: US20140066981A1
Автор: Eggert Christoph, Heckroth Heike
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to a polyurea system encompassing as component A) isocyanate-functional prepolymers obtainable by reaction of aliphatic isocyanates A1) with polyols A2), which can in particular have a number average molecular weight of ≧400 g/mol and an average OH functionality of 2 to 6, as component B) amino-functional compounds of general formula (I) in which X is an organic residue comprising a tertiary amino function, having no Zerewitinoff active hydrogen, Ris a CH—COORresidue, in which Ris an organic residue having no Zerewitinoff active hydrogen, a linear or branched C1 to C4 alkyl residue, a cyclopentyl or cyclohexyl residue or H, Ris an organic residue having no Zerewitinoff active hydrogen, n is an integer ≧2 or ≦3, in particular for closing, binding, bonding or covering cell tissue, and to a metering system for the polyurea system according to the invention. 114-. (canceled)17. The polyurea system according to claim 16 , wherein R claim 16 , R claim 16 , Rare claim 16 , each independently of one another or simultaneously claim 16 , a linear or branched claim 16 , saturated organic residue that is optionally also substituted in the chain with heteroatoms claim 16 , in particular a linear or branched claim 16 , saturated claim 16 , aliphatic C1 to C10 claim 16 , preferably C2 to C8 and particularly preferably C2 to C6 hydrocarbon residue.18. The polyurea system according to claim 17 , wherein R claim 17 , R claim 17 , Rare claim 17 , each independently of one another or simultaneously claim 17 , a methyl claim 17 , ethyl claim 17 , propyl or butyl residue claim 17 , wherein at least one of R claim 17 , R claim 17 , Ris a methylene claim 17 , ethylene claim 17 , propylene or butylene residue.19. The polyurea system according to wherein R claim 15 , Rand optionally Rare claim 15 , each independently of one another or simultaneously claim 15 , a linear or branched C1 to C10 claim 15 , preferably C1 to C8 claim 15 , particularly preferably C2 to ...

Подробнее
Номер записи: 80
13-03-2014 дата публикации

ROLLED COLLAGEN CARRIER

Номер: US20140072612A1
Автор: Bertelsen Poul, Blanka Ingrid, Braender Henrik, Larsen Henrik Neuschaefer, Pedersen Pernille Dybendal, Schoenhofer Wolfgang
Принадлежит: TAKEDA PHARMA A/S

The invention relates to a process for the preparation of a rolled compressed collagen carrier and a process for un-rolling said rolled compressed collagen carrier. Said rolled compressed collagen carrier is ready for use in minimally invasive surgery. The invention also relates to a rolled compressed collagen carrier for use in the prevention or treatment of injury associated with performing minimally invasive surgery. 160.-. (canceled)62. A process according to claim 61 , wherein the coiling is performed by gripping the collagen carrier using at least one pair of tweezers or pincers.63. A process according to claim 61 , wherein at least the coating layer of said collagen carrier is humidified claim 61 , and wherein the coating layer has been humidified using a solvent.64. A process according to claim 63 , wherein the solvent comprises ethanol.65. A process according to claim 61 , further comprising compressing the collagen carrier to reduce the thickness of the collagen carrier.66. A process according to claim 61 , further comprising arranging the form-stable coiled collagen carrier in a container and subsequently sealing the container.67. A coiled collagen carrier obtainable by the process of .68. A method of surgery comprising administering to a patient in need thereof the coiled collagen carrier according to .69. A method of preventing or treating an injury associated with performing minimally invasive surgery in a patient claim 67 , comprising administering to a patient in need thereof the coiled collagen carrier according to .70. A method of preventing or treating an injury associated with performing endoscopic surgery in a patient claim 67 , comprising administering to a patient in need thereof the coiled collagen carrier according to .71. A method of preventing injury to or treating a tissue in need of sealing and/or glueing claim 67 , comprising administering to a patient in need thereof the coiled collagen carrier according to .72. A coiled collagen ...

Подробнее
Номер записи: 81
13-03-2014 дата публикации

POLY(OCTYLCYANOACRYLATE)-POLYISOBUTYLENE POLYMER CONETWORK, METHOD FOR THE PRODUCTION THEREOF AND USES THEREOF

Номер: US20140073743A1
Автор: Erdodi Gabor, Gasser Ryan, Kennedy Joseph, Tang Juay Seng
Принадлежит: THE UNIVERSITY OF AKRON

A polymer conetwork formed from the polymerization reaction of octyl-cyanoacrylate and a tri-telechelic star polymer comprising polyisobutylene terminated with cyanoacrylate groups (Ø(PIB-CA)), wherein the ratio of octyl cyanoacrylate to Ø(PIB-CA)is from about 10:1 to about 40:1. 1. A polymer conetwork formed from the polymerization reaction of:{'sub': 3', '3, 'octyl-cyanoacrylate and a tri-telechelic star polymer comprising polyisobutylene terminated with cyanoacrylate groups (Ø(PIB-CA)), wherein the ratio of octyl cyanoacrylate to Ø(PIB-CA)is from about 10:1 to about 40:1.'}2. The polymer conetwork according to claim 1 , wherein polymerization reaction is initiated by nucleophlic groups located on the surface to be covered by the polymer conetwork.3. The polymer conetwork according to claim 2 , wherein the surface to be covered is skin.4. The polymer conetwork according to any of to claim 2 , wherein the polymer conetwork exhibits higher elongation than a homopolymer of octyl cyanoacrylate.5. The polymer conetwork according to any of to claim 2 , wherein the polymer conetwork exhibits a strength of at least 5N and sufficient to maintain two pieces of skin together.6. Use of the polymer conetwork of for wound closure.7. Use of the polymer conetwork of for sealing surgical cuts and puncture wounds.8. Use of polymer conetwork of as an orthopedic sealant.9. Use of polymer conetwork of for repair of torn annulus. This application claims the benefit of U.S. Provisional Patent Application No. 61/441,813, filed Feb. 11, 2011 and claims the benefit of U.S. Provisional Patent Application No. 61/559,778, filed Nov. 15, 2011, both of which are hereby incorporated by reference.This invention relates to a polyisobutylene-based conetwork and, more particularly, to a poly(octyl cyanoacrylate)-polyisobutylene conetwork. In addition to the polymer conetwork, a method of producing the polymer conetwork is provided, as well as a number of uses for the polymer conetwork are disclosed. ...

Подробнее
Номер записи: 82
27-03-2014 дата публикации

Adhesive composition for soft tissues, adhesive composition for wound dressing or wound dressing composition

Номер: US20140086967A1
Автор: Hiroshi Naruse, Noriaki Asada
Принадлежит: Mitsui Chemicals Inc

The present invention provides an adhesive composition for soft tissues, an adhesive composition for wound dressing or a wound dressing composition, not only having low toxicity, low harmfulness and high adhesive strength but also being excellent in workability during application and being capable of forming films of excellent properties. The compound of the present invention is comprised a monomer (A), polymer particles (B) having a specific weight-average molecular weight and a specific volume mean particle diameter, and a polymerization initiator composition (C) containing an organoboron compound is produced.

Подробнее
Номер записи: 83
10-04-2014 дата публикации

BIORESORBABLE EMBOLIZATION MICROSPHERES

Номер: US20140099374A1
Автор: Golzarian Jafar, Weng Lihui
Принадлежит: Regents of the University of Minnesota

The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin. 1. An embolic material comprising at least one microsphere comprising carboxymethyl chitosan crosslinked with carboxymethyl cellulose.2. The embolic material of claim 1 , wherein the microsphere comprises a diameter between about 100 micrometers and about 1200 micrometers.3. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 300 micrometers and about 500 micrometers.4. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 100 micrometers and about 300 micrometers.5. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 700 micrometers and about 900 micrometers.6. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 900 micrometers and about 1200 micrometers.7. The embolic material of claim 1 , wherein the microsphere further comprises a therapeutic agent.8. The embolic material of claim 7 , wherein the therapeutic agent comprises a chemotherapeutic agent.9. The embolic material of claim 7 , wherein the therapeutic agent comprises at least one positively charged functional group.10. The embolic material of claim 7 , wherein the therapeutic agent comprises at least one of irinotecan claim 7 , ambroxol claim 7 , or doxorubicin.11. The embolic material of claim 7 , wherein a concentration of the therapeutic agent is between about 0.3 milligram of therapeutic agent per milligram of dry microsphere and about 0.75 milligram of therapeutic agent per milligram of dry microsphere.12. The embolic material of claim 1 , wherein ...

Подробнее
Номер записи: 84
07-01-2021 дата публикации

METHODS FOR DENSIFICATION AND STRUCTURAL ALIGNMENT OF BIOMINERALIZED MATERIAL

Номер: US20210000697A1
Автор: GRAHAM Uschi M., LIPKA Stephen M.
Принадлежит:

A method of vacuum densification and simultaneous alignment of mineral components formed inside biomineralized organoids includes providing a pressing die system that includes a push rod arranged within a sleeve, a sample chamber, and a semi-porous support plate equipped with a vacuum pump system. A hydrated biomineralized organoid sample, including a mineral component, is inserted into the sample chamber. The biomineralized organoid sample is mechanically compressed by exerting a force via the push rod so that a solid fraction of the biomineralized organoid sample is compressed while a portion of a liquid fraction passes through the semi-porous support plate, thereby leaving the biomineralized organoid sample in a partially dehydrated state. The portion of the liquid fraction that passes through the semi-porous support plate is removed via the vacuum pump system. Mechanical compression of the solid fraction and vacuum removal of the portion of the liquid fraction facilitates an increase in density of the mineral component and an increase in alignment of particles that comprise the mineral component. 1. A method of vacuum densification and simultaneous alignment of mineral components formed inside biomineralized organoids , the method comprising:providing a pressing die system that includes a push rod arranged within a sleeve, a sample chamber, and a semi-porous support plate equipped with a vacuum pump system;inserting a hydrated biomineralized organoid sample, including a mineral component, into the sample chamber;mechanically compressing the biomineralized organoid sample, by exerting a force via the push rod, so that a solid fraction of the biomineralized organoid sample is compressed while a portion of a liquid fraction passes through the semi-porous support plate, thereby leaving the biomineralized organoid sample in a partially dehydrated state; andremoving the portion of the liquid fraction that passes through the semi-porous support plate via the vacuum ...

Подробнее
Номер записи: 85
07-01-2021 дата публикации

Composition for hemostasis and container comprising same

Номер: US20210001002A1
Автор: Bae Sang-Hee, Ko Jae-Hyung, Park Si-Nae
Принадлежит:

The present invention relates to a composition for hemostasis which contains collagen, stabilizer, and thrombin, and a container including the same. The present invention is applicable to a bleeding patient requiring emergency treatment with a simple method of use. There is no toxicity and no problem of blood infection. A biodegradation rate is fast. In this regard, the present invention achieves an excellent hemostatic effect. Therefore, the composition for hemostasis is useful as a hemostat. 1. A composition for hemostasis comprising collagen;stabilizer; andthrombin,wherein the stabilizer is disposed between the collagen and the thrombin so that the collagen and the thrombin are separated from each other.2. The composition of claim 1 , wherein the collagen is crosslinked collagen.3. The composition of claim 2 , wherein the crosslinked collagen is prepared using a preparing method including(S1) a step of treating the collagen with ethanol or methanol,(S2) a step of preparing collagen solution having pH 2 to pH 4 by adding acid to the collagen treated in the step (S1),(S3) a step of preparing esterified collagen by performing centrifugation on the collagen solution prepared in the step (S2) after bringing the collagen solution into a neutral state,(S4) a step of preparing the crosslinked collagen by adding a crosslinking agent to esterified collagen prepared in the step of (S3), and(S5) a step of performing freeze drying on the crosslinked collagen prepared in the step (S4) after the crosslinked collagen is dispersed into purified water.4. The composition of claim 2 , wherein a molecular weight of the crosslinked collagen is 100 claim 2 ,000 to 1 claim 2 ,000 claim 2 ,000 Dalton.5. The composition of claim 1 , wherein the collagen is included as much as 40 to 97 weight % in a gross weight of the composition for hemostasis.6. The composition of claim 1 , wherein the stabilizer is at least one selected from a group consisting of albumin (human serum albumin) claim 1 , ...

Подробнее
Номер записи: 86
04-01-2018 дата публикации

ONE COMPONENT FIBRIN GLUE COMPRISING A POLYMERIZATION INHIBITOR

Номер: US20180000982A1
Автор: DeAnglis Ashley, Doron Sivan, Nur Israel, Pilpel Yair, Zherdev Yuri
Принадлежит:

Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations. 113-. (canceled)14. A method for preparing a sealant at a surface comprising: providing a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 , 21 , 22 , 23 , 24 , and 25° C.; and applying the formulation to the surface under conditions which facilitate fibrin polymerization at the surface.15. The method of claim 14 , wherein the conditions comprise removing claim 14 , blocking claim 14 , neutralizing and/or diluting the GPRP peptide.1620-. (canceled)21. A method of healing claim 14 , sealing and/or reducing blood loss in a subject in need claim 14 , comprising applying to the subject an effective amount of a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 claim 14 , 21 claim 14 , 22 claim 14 , 23 claim 14 , 24 claim 14 , and 25° C.22. (canceled) The instant application contains a Sequence Listing, which is submitted concomitantly with this application via EFS-Web in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 22, 2013, is named “sequencelisting” and is 8 ...

Подробнее
Номер записи: 87
04-01-2018 дата публикации

HYDROGELS AND USE THEREOF IN ANASTOMOSIS PROCEDURES

Номер: US20180000983A1
Автор: Brandacher Gerald, Brat Gabriel, Grahammer Johanna, Schneider Joel, SMITH Daniel
Принадлежит:

This disclosure provides novel hydrogels that can undergo multiple gel-sol transitions and methods of making and using such hydrogels, particularly in anastomosis procedures. The peptide hydrogels comprising a fibrillar network of peptides that are in an amphiphilic β-hairpin conformation. The peptides comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel. Isolated peptides for making the disclosed hydrogels are provided, as are methods of using the peptide hydrogels in anastomosis procedures. 1. A peptide hydrogel comprising a fibrillar network of peptides , wherein:the hydrogel undergoes a gel-sol phase transition upon application of shear stress, and a sol-gel phase transition upon removal of the shear stress; andthe peptides are in an amphiphilic β-hairpin conformation and comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel.2. The peptide hydrogel of claim 1 , wherein:the amphiphilic β-hairpin conformation comprises a β-turn, a first β-strand, a second β-strand, a hydrophobic face, and a hydrophilic face;the assembly of the peptides in the fibrillar network comprises hydrophobic interactions between the hydrophobic faces of the peptides;the first β-strand comprises the photocaged glutamate residue, the second β-strand comprises a glycine residue, and the sidechains of the photocaged glutamate residue and the glycine residue are proximal to each other on the hydrophobic faces of the peptides; anduncaging the photocaged glutamate residues disrupts the hydrophobic interactions between the peptides by exposing negative charges of the glutamate residues, thereby disrupting the fibrillar network and triggering the irreversible gel-sol phase transition ...

Подробнее
Номер записи: 88
02-01-2020 дата публикации

A MEDICAL IMPLANT AND A METHOD OF COATING A MEDICAL IMPLANT

Номер: US20200000976A1
Автор: JEFFERY Christopher Arnold
Принадлежит: Field Orthopaedics Pty Ltd

A synthetic bead is for implantation within the body of an animal or human body. The bead includes a surface defining a shape having a bulk volume of the bead. The surface of the bead is coated with at least a first therapeutic agent to form an inner layer; and an outer layer includes a biodegradable polymer and a second therapeutic agent positioned above the inner layer. 1. A medical implant comprising an implant surface , the surface comprising:an inner layer comprising a first bioceramic material and a first therapeutic agent; andan outer layer comprising a biodegradable polymer and a second therapeutic agent.2. A medical implant in accordance with wherein the outer layer further comprises a second bioceramic material.3. A medical implant in accordance with wherein the second bioceramic material is dispersed throughout the matrix of the biodegradable polymer.4. A medical implant in accordance with any one of the preceding claims wherein the biodegradable polymer is selected from the group comprising: Poly lactic acid (PLA) claim 2 , poly glycolic acid (PGA) claim 2 , Poly lactic co-glycolic acid (PLGA) claim 2 , and copolymers with polyethylene glycol (PEG); polyanhydrides claim 2 , poly(ortho)esters claim 2 , polyurethanes claim 2 , poly(butyric acid) claim 2 , poly(valeric acid) claim 2 , poly(lactide-co-caprolactone) and trimethylene carbonate and combinations and co-polymers thereof.5. A medical implant in accordance with any one of the preceding claims wherein the bioceramic material is selected from the group comprising of hydroxyapatite claim 2 , tricalcium phosphate claim 2 , bioglass claim 2 , calcium phosphate or bone or a combination thereof.6. A medical implant in accordance with any one of the preceding claims wherein the bioceramic material is hydroxyapatite and wherein the hydroxyapatite comprises one or more of the following ions selected from the group consisting of calcium claim 2 , phosphates claim 2 , fluorine claim 2 , strontium claim 2 , ...

Подробнее
Номер записи: 89
05-01-2017 дата публикации

Self-Assembling Biomimetic Hydrogels Having Bioadhesive Properties

Номер: US20170000923A1
Автор: IFTODE Cristina, JOHNSON Bryan, KADLOWEC Jennifer, KUBINSKI Pamela, TULENKO Thomas N., Vernengo Andrea J., WILTSEY Craig
Принадлежит: ROWAN UNIVERSITY

The disclosure relates to a composition that is liquid at a temperature below the body temperature of a mammal and that solidifies at or above the body temperature of the mammal. The composition includes a thermally-desolubilizable polymer interspersed with a polymeric component of extracellular matrix and an encapsulated form of an amine compound (preferably an aminated component of extracellular matrix) that is de-encapsulated in the body of the mammal. The polymeric component is able to form covalent bonds with amine moieties in the aminated component, in one or more tissues in the body of the mammal, or both. Upon injection off liquid suspension of these components into the body of the mammal, the thermally-desolubilizable polymer condenses, entrapping the polymeric component. The polymeric component binds covalently with a tissue in the body, and the aminated component end-caps the remaining reactive moieties of the polymeric component, forming a matrix at the site of injection. The disclosure also relates to uses of such compositions for forming a matrix on or within the body of a mammal. The compositions have a variety of uses, such as bioadhesives, as sealants for ruptured tissues, as drug or imaging agent depots, or as mechanical cushions. 1101-. (canceled)102. A method of forming a solidified matrix fixed within the body of a mammal , the method comprising: a) a biocompatible thermally-desolubilizable (TD) polymer selected from the group consisting of poly(ethylene oxides) (PEOs), poly(propylene oxides) (PPOs), copolymers of PEO and poly(lactide acid) (PLA), poly (n-isopropyl acrylamides) (PNIPPAms), mixtures and copolymers thereof, wherein the polymer exists in an extended form below a critical solution temperature (CST) that is lower than the normal body temperature of the mammal and in a condensed form at or above the CST;', 'b) an aminated component of a mammalian extracellular matrix, in a releasable encapsulated form, wherein the aminated component ...

Подробнее
Номер записи: 90
07-01-2021 дата публикации

BIODEGRADABLE BLOCK COPOLYMER

Номер: US20210002432A1
Автор: Fujita Masaki, Kidoba Kazuyuki, Kogawa Taisuke, Koyamatsu Yuichi, Tanahashi Kazuhiro
Принадлежит:

A biodegradable block copolymer has high conformability and excellent degradability. The block copolymer including a polyalkylene glycol block and a polyhydroxyalkanoic acid block, wherein the mass ratio of the polyalkylene glycol block with respect to the total mass is 10 to 60%; the carbonyl carbon has a carbon nuclear relaxation time T1ρ of not more than 20 ms; and the block copolymer satisfies Equation (1): χ=χ1×χ2>20 (1) χ1: crystallization rate of the polyalkylene glycol block; χ2: crystallization rate of a poly-A block, wherein A represents, among the repeat units contained in the polyhydroxyalkanoic acid block, a repeat unit whose homopolymer composed of the same repeat units has a highest crystallization rate. 19.-. (canceled)11. The block copolymer according to claim 10 , wherein the polyhydroxyalkanoic acid block comprises a repeat unit derived from a monomer selected from the group consisting of lactic acid claim 10 , glycolic acid claim 10 , and caprolactone.12. The block copolymer according to claim 10 , wherein a mass ratio of the repeat unit derived from caprolactone with respect to the total mass of the block copolymer is 20 to 80%.13. The block copolymer according to claim 10 , wherein the weight average molecular weight of the polyalkylene glycol block is 7 claim 10 ,000 to 170 claim 10 ,000.18. A medical material comprising: the block copolymer according to ; and a molded article to be coated with the block copolymer.19. A medical material comprising: the block copolymer according to ; and a molded article to be coated with the block copolymer.20. A medical material comprising: the block copolymer according to ; and a molded article to be coated with the block copolymer.21. A medical material comprising: the block copolymer according to ; and a molded article to be coated with the block copolymer.22. A medical material comprising: the block copolymer according to ; and a molded article to be coated with the block copolymer.23. A medical material ...

Подробнее
Номер записи: 91
01-01-2015 дата публикации

STIMULI-RESPONSIVE MATERIAL AND MEDICAL MATERIAL

Номер: US20150005409A1
Автор: Horiguchi Tomoyuki, NARUSE Yoshihiro, Takeuchi Kosaku, Tanahashi Kazuhiro, YAMASHITA Kohei, Yokoe Makito
Принадлежит:

A stimuli-responsive material includes a stimuli-responsive polymer, fibers and water, wherein the fibers have a number average diameter of 1 to 900 nm and are present in the stimuli-responsive material in a dispersed state; and a medical material and an anti-adhesive material, each of which includes a stimuli-responsive material including a stimuli-responsive polymer, fibers and water, wherein the fibers have a number average diameter of 1 to 900 nm and are present in the stimuli-responsive material in a dispersed state. 114-. (canceled)15. A stimuli-responsive material comprising a stimuli-responsive polymer , fibers and water , wherein the fibers are dispersed and have a number average diameter of 1 to 900 nm.16. The stimuli-responsive material according to claim 15 , wherein a weight ratio (stimuli-responsive polymer/fiber) of the stimuli-responsive polymer to the fiber is 5 to 100.17. The stimuli-responsive material according to claim 15 , wherein the stimuli-responsive polymer is a temperature-responsive polymer having a lower critical solution temperature.18. The stimuli-responsive material according to claim 15 , wherein a difference of Solubility Parameters of basic chemical structure of the stimuli-responsive polymer and the fiber is 0 to 5.19. The stimuli-responsive material according to claim 15 , wherein the stimuli-responsive polymer and the fiber have a common basic chemical structure selected from amide unit claim 15 , hydroxy acid unit and monosaccharide unit.20. The stimuli-responsive material according to claim 15 , wherein the stimuli-responsive polymer is a poly(N-isopropyl acrylamide)-based polymer and the fiber is a polyamide-based fiber.21. The stimuli-responsive material according to claim 15 , wherein the stimuli-responsive polymer comprises a lactic acid unit and the fiber is a polylactic acid.22. The stimuli-responsive material according to claim 15 , wherein the fiber has a fiber length of 0.01 to 10.0 mm.23. The stimuli-responsive ...

Подробнее
Номер записи: 92
20-01-2022 дата публикации

Single-use contact tip for tonometer

Номер: US20220015631A1
Автор: David A. Taylor, Mary M. MURPHY
Принадлежит: Reichert Inc

A contact tip for a contact tonometer has a body including a contact surface, and a coating applied to the contact surface. The coating includes a light-activated material and a biocompatible water soluble adhesive for adhering the coating to the contact surface. The water soluble adhesive dissolves upon contact with the corneal tear film during a tonometric measurement, thereby releasing the light-activated material into the tear film. The present disclosure further provides a single-use tonometer contact tip product which includes a sterilized contact tip having the mentioned contact surface coating, and an opaque package containing the sterilized contact tip.

Подробнее
Номер записи: 93
20-01-2022 дата публикации

Dental glass ionomer cement compositions containing polysaccharide nanofiber

Номер: US20220015991A1
Автор: Katsuya Kimoto, Shuji Sakamoto, Shun Shimosoyama
Принадлежит: Shofu Inc

An object of the present invention is to provide a dental glass ionomer cement composition having high safety to a human body and sufficient working time, in which mechanical properties, mixing ability in hand mixing and dischargeability out of a container after mechanical kneading are simultaneously improved with satisfactory balance compared with the prior art. Disclosed is a dental glass ionomer cement composition including 0.001 to 3% by weight of (a) a polysaccharide nanofiber having an aspect ratio of 100 or more and an average fiber diameter of 100 nm or less.

Подробнее
Номер записи: 94
20-01-2022 дата публикации

TWO-REACTANT SHEET-SHAPED ADHESIVE/REINFORCEMENT FOR TISSUES

Номер: US20220016311A1
Автор: FUJIMURA Motoki, Hyon Suong-Hyu, Hyon Woogi, KOJITANI Yusuke, OSADA Shinichi, TANIDA Shuhei
Принадлежит:

A sheet-shaped tissue adhesive/reinforcement includes a base sheet having biodegradability and a communicative porous structure, and an adhesive resin layer fixed and formed on the base sheet. The adhesive resin layer includes a first reactant made of an aldehyded glycan and a second reactant made of partially carboxylated polylysine, and has a molar ratio of 1 as a ratio of an aldehyde group of the first reactant to an amine group of the second reactant. The adhesive resin layer has a structure of granules derived from powder of the first reactant, and a connecting layer derived from the second reactant. The connecting layer connects the granules to each other and fixes each of the granules onto the base sheet, throughout the sheet-shaped tissue adhesive/reinforcement. 1. A sheet-shaped tissue adhesive/reinforcement comprising:a base sheet having biodegradability and a communicative porous structure; andan adhesive resin layer fixed and formed on the base sheet,the adhesive resin layer includinga first reactant made of aldehyded glycan, anda second reactant made of partially carboxylated polylysine, and the adhesive resin layer havinga molar ratio of 1 as a ratio of an aldehyde group of the first reactant to an amine group of the second reactant,a structure of granules derived from powder of the first reactant, anda connecting layer derived from the second reactant, the connecting layer connecting the granules with each other and fixing each of the granules onto the base sheet, throughout the sheet-shaped tissue adhesive/reinforcement.2. The sheet-shaped tissue adhesive/reinforcement according to claim 1 , whereinthe base sheet is non-woven fabric, woven fabric, knitted fabric, mesh sheet, sponge sheet, or other continuous porous sheet, and has a thickness of 15 μm to 500 μm, andthe adhesive resin layer has a thickness of 100 μm to 800 μm.3. The sheet-shaped tissue adhesive/reinforcement according to claim 1 , wherein the granules derived from the powder of the ...

Подробнее
Номер записи: 95
12-01-2017 дата публикации

IMPLANTATION DEVICES INCLUDING HYDROGEL FILAMENTS

Номер: US20170007264A1
Автор: Constant Michael J., Cruise Gregory M., Keeley Edward Michael, Tran Terrance T.
Принадлежит:

Described are devices for implantation comprising a hydrogel filament wherein the hydrogel filament includes a low molecular weight ethylenically unsaturated macromer, an ethylenically unsaturated monomer, and a visualization agent. Methods of making and using these devices are also described. 1. A device for implantation comprising:a hydrogel filament attached to a coupler wherein the coupler is attached to a pusher,wherein the hydrogel filament includes a low molecular weight ethylenically unsaturated macromer; an ethylenically unsaturated monomer; and a visualization agent,wherein said device contains no support members.2. The device of claim 1 , wherein said macromer has a molecular weight of about 100 grams/mole to about 5000 grams/mole.3. The device of claim 1 , wherein said macromer comprises polyethylene glycol claim 1 , propylene glycol claim 1 , poly(tetramethylene oxide) claim 1 , poly(ethylene glycol) diacrylamide claim 1 , poly(ethylene glycol) diacrylate claim 1 , poly(ethylene glycol) dimethacrylate claim 1 , derivatives thereof claim 1 , or combinations thereof.4. The device of claim 1 , wherein said visualization agent comprises an aromatic ring having a single unsaturation point and at least one iodine atom.5. The device of claim 1 , wherein said visualization agent comprises barium sulfate claim 1 , gadolinium claim 1 , or iron oxide.6. The device of claim 5 , wherein said visualization agent is barium sulfate.7. The device of claim 1 , wherein said ethylenically unsaturated monomer and said visualization agent comprise 2 claim 1 ,4 claim 1 ,6-triiodophenyl penta-4-enoate claim 1 , 5-acrylamido-2 claim 1 ,4 claim 1 ,6-triiodo-n claim 1 ,n′-bis-(2 claim 1 ,3 dihydroxypropyl) isophthalamide claim 1 , derivatives thereof claim 1 , or combinations thereof.8. The device of claim 1 , wherein said macromer and said monomer are crosslinked with N claim 1 ,N claim 1 ,N′ claim 1 ,N′-tetramethylethylenediamine claim 1 , ammonium persulfate claim 1 , ...

Подробнее
Номер записи: 96
14-01-2016 дата публикации

Adhesive Composition

Номер: US20160008505A1
Автор: Jensen Jarl, Keng Ta Kang, Ramjit Ravi
Принадлежит: EUROMED INC.

The present invention relates to an adhesive composition applicable to skin comprising: (i) a polar oil or fat including (a) at least one triglyceride and/or (b) at least one fatty acid of the formula R—COH, wherein R is a Cto Calkyl group; and (ii) at least one homopolymer, and/or copolymer. This invention also relates to a medical adhesive device including such adhesive composition. 2. (canceled)3. (canceled)4. (canceled)5. The adhesive composition of further comprising at least one tackifier.6. The adhesive composition of claim 5 , wherein the tackifier is selected from the group consisting of natural rosin claim 5 , modified rosin claim 5 , glycerol ester of natural rosin claim 5 , glycerol ester of modified rosin claim 5 , pentaerythritol ester of natural rosin claim 5 , pentaerythritol ester of modified rosin claim 5 , phenolic-modified terpene resin claim 5 , aliphatic petroleum hydrocarbon resin claim 5 , and cycloaliphatic resin.7. (canceled)8. (canceled)9. The adhesive composition of claim 1 , wherein the base polymer comprises at least two immiscible monomers.10. The adhesive composition of further comprising a hydrophilic fluid-absorbing gum or gel-thickener claim 1 , wherein the gum or gel-thickener is cationic claim 1 , anionic claim 1 , or non-ionic.11. The adhesive composition of claim 10 , wherein the gel-thickener is a water soluble or swellable hydrocolloid or a mixture thereof.12. The adhesive composition of claim 11 , wherein the gel-thickener is selected from a group consisting of carboxymethylcellulose claim 11 , hydroxyethylcellulose (HEC) claim 11 , hydroxypropylcellulose (HPC) claim 11 , pectin claim 11 , carrageenan claim 11 , and gelatin.13. A medical adhesive device comprising an adhesive composition comprising coconut oil claim 11 , a mineral oil claim 11 , and a base polymer.14. The adhesive device of claim 13 , wherein the adhesive composition further comprises a tackifier.15. The adhesive device of claim 14 , wherein the tackifier is ...

Подробнее
Номер записи: 97
11-01-2018 дата публикации

OSTOMY DEVICE

Номер: US20180008451A1
Автор: Stroebech Esben
Принадлежит:

Disclosed is an ostomy device with an adhesive wafer for attachment to a skin surface of a user and a collecting bag for collecting output from a stoma. The collecting bag is connected to the adhesive wafer, and the adhesive wafer has a through-going hole for accommodating the stoma of the user. The adhesive wafer includes a backing layer, a first switchable adhesive composition (), a second absorbent adhesive composition (), and a release liner. 125-. (canceled)26. An ostomy device comprising an adhesive wafer for attachment to a skin surface of a user , and a collecting bag connected to the adhesive wafer; the adhesive wafer having a through-going hole for accommodating the stoma of the user; and the adhesive wafer comprising a backing layer , a first switchable adhesive composition , a second absorbent adhesive composition , and a release liner , wherein the adhesive wafer has a central part adjacent to the hole for accommodating the stoma and a peripheral part adjacent to an edge of the adhesive wafer away from the hole , and wherein the second absorbent adhesive composition is located at least in the central part of the adhesive wafer , wherein the release liner is in contact with the first switchable adhesive composition in the peripheral part of the adhesive wafer , and wherein the release liner is in contact with the second absorbent adhesive composition in the central part of the adhesive wafer.27. The ostomy device according to claim 26 , wherein the switchable adhesive composition is switchable from a high-tack state with a first peel force to a lower-tack state with a second peel force.28. The ostomy device according to claim 27 , wherein the first peel force is higher than the second peel force.29. The ostomy device according to claim 27 , wherein the peel force is measured by a 90 degree peel test.30. The ostomy device according to claim 27 , wherein a reduction in peel force between the first peel force and the second peel force is at least 50%.31. ...

Подробнее
Номер записи: 98
08-01-2015 дата публикации

Temporary Embolization Using Inverse Thermosensitive Polymers

Номер: US20150010471A1
Автор: Raymond Jean, Schwarz Alexander
Принадлежит:

One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter, and which compositions gel at or below body temperature. In certain embodiments of the methods of embolization, said composition further comprises a marker molecule, such as a dye, radiopaque, or an MRI-visible compound. 1. A method of temporarily embolizing a vascular site in a mammal , comprising the step of:introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, thereby temporarily embolizing a vascular site of said mammal.2. The method of claim 1 , wherein said mammal is a human.3. The method of claim 1 , wherein the transition temperature of said inverse thermosensitive polymer is between about 10 C and about 40 C.4. The method of claim 1 , wherein the volume of the inverse thermosensitive polymer between its transition temperature and physiological temperature is between about 80% and about 150% of the volume of the inverse thermosensitive polymer below its transition temperature.5. The method of claim 1 , wherein said inverse thermosensitive polymer is a block copolymer claim 1 , random copolymer claim 1 , graft polymer claim 1 , or branched copolymer.6. The method of claim 1 , wherein said inverse thermosensitive polymer is a block copolymer.7. The method of claim 1 , wherein said inverse thermosensitive polymer is a polyoxyalkylene block copolymer.8. The method of claim 1 , wherein said inverse thermosensitive polymer is a poloxamer or poloxamine.9. The method of claim 1 , wherein said inverse thermosensitive polymer is a poloxamer.10. The method of claim 1 , wherein said inverse thermosensitive ...

Подробнее
Номер записи: 99
08-01-2015 дата публикации

ANTI-ADHESION POLYMER COMPOSITION CAPABLE OF SUPPORTING GROWTH FACTOR

Номер: US20150010490A1
Автор: Kim Jung Ju, Ryu Hyun Seung, Seo Jun Hyuk, So Jung Won
Принадлежит: CG BIO CO., LTD.

The present invention relates to an anti-adhesion polymer composition capable of supporting growth factor, which effectively exhibits anti-adhesion function and, at the same time, has an excellent adhesive property so as to be able to easily and continuously adhere to a wound site, has antibacterial and hemostatic properties, and is composed of an injectable formulation suitable for use in minimally invasive surgery, laparoscopic surgery or the like. The anti-adhesion polymer composition capable of supporting growth factor comprises: 24-50 wt % of a polyethyleneglycol-polypropyleneglycol-polyethyleneglycol (PEG-PPG-PEG) block copolymer having a polyethyleneglycol (PEG) content of 65-85 wt % and a molecular weight of 6,000-20,000 Da; 0.03-5 wt % of gelatin; 0.03-5 wt % of chitosan; and distilled water. 1. An anti-adhesion polymer composition capable of supporting growth factor , the composition comprising: 24-50 wt % of a polyethyleneglycol-polypropyleneglycol-polyethyleneglycol (PEG-PPG-PEG) block copolymer having a polyethyleneglycol (PEG) content of 65-85 wt % and a molecular weight of 6 ,000-20 ,000 Da; 0.03-5 wt % gelatin; 0.03-5 wt % of chitosan; and distilled water.2. The anti-adhesion polymer composition of claim 1 , wherein the block copolymer is composed of two kinds of block copolymers having different PEG contents.3. The anti-adhesion polymer composition of claim 2 , wherein the cont or each of the block copolymers in the composition is 12-25 wt %.4. The anti-adhesion polymer composition of claim 1 , further comprising glycerol as a stabilizer for suppressing phase separation of the composition.5. The anti-adhesion polymer composition of claim 1 , further comprising at least one growth factor selected from among epidermal growth factor (EGF claim 1 , beta-urogastrone) claim 1 , heparin-binding EGF-like growth factor (HB-EGF) claim 1 , transforming growth factor-α (TGF-α) and fibroblast growth factors (FGFs). The present invention relates to an anti- ...

Подробнее
Номер записи: 100